Download:
pdf |
pdfOMB Number:
Expiration Date:
0920-0612
03/31/2025
WISEWOMAN
Program
MDE Manual
Edition 18.3
Public reporting burden of this collection of information is estimated to average 24 hours per
program including the time for reviewing instructions, searching existing data sources, gathering and
maintaining the data needed, and completing and reviewing the collection of information. An agency
may not conduct or sponsor, and a person is not required to respond to a collection of information it
displays a currently valid OMB control number. Send comments regarding this burden estimate or
any other aspect of this collection of information, including suggestions for reducing this burden to
CDC/ATSDR Reports, Clearance Officer, 1600 Clifton Road NE, MS D-74, Atlanta, GA 30333. Attn:
PRA (0920-0612). Do not send the completed form to this address.
CONTENTS
1. INTRODUCTION .................................................................................................................. 1
2. ADMINISTRATIVE MDE SPECIFICATIONS ........................................................................ 3
a. Summary of Administrative MDEs ................................................................................... 4
b. Administrative MDE Specifications .................................................................................. 5
Item 1a: StFIPS .......................................................................................................... 5
Item 1b: HdANSI ........................................................................................................ 6
Item 1c: EnrollSiteID ................................................................................................... 7
Item 1d: ScreenSiteID ................................................................................................ 8
Item 2a: TimePer ........................................................................................................ 9
Item 2b: NScreen ..................................................................................................... 10
Item 2c: Type............................................................................................................ 11
Item 2d: Navigation................................................................................................... 12
Item 3a: EncodeID .................................................................................................... 13
3. SCREENING AND ASSESSMENT MDE SPECIFICATIONS ............................................. 14
a. Summary of Screening and Assessment MDEs ............................................................ 15
b. Screening and Assessment MDE Specifications ........................................................... 17
Item 3b: ResANSI ..................................................................................................... 17
Item 3c: ZIP .............................................................................................................. 18
Item 3d: MYB............................................................................................................ 19
Item 3e: Latino.......................................................................................................... 20
Item 3f: Race1 .......................................................................................................... 21
Item 3g: Race2 ......................................................................................................... 22
Item 3h: Education.................................................................................................... 23
Item 3i: Language ..................................................................................................... 24
Item 4a: SRC ............................................................................................................ 26
Item 4b: SRHA ......................................................................................................... 27
Item 5a: Meds........................................................................................................... 29
Item 5b: Aspirin ........................................................................................................ 31
Item 5c: MedAdhere ................................................................................................. 32
Item 5d: Monitored.................................................................................................... 34
Item 6a: BPHome ..................................................................................................... 35
Item 6b: BPFreq ....................................................................................................... 36
Item 6c: BPSend ...................................................................................................... 37
Item 7a: FruitVeg ...................................................................................................... 38
Item 7b: Fish............................................................................................................. 39
Item 7c: Grains ......................................................................................................... 40
Item 7d: Sugar .......................................................................................................... 41
Item 7e: SaltWatch ................................................................................................... 42
Item 7f: AlcFreq ........................................................................................................ 43
Item 7g: AlcDay ........................................................................................................ 44
Item 8a: PA .............................................................................................................. 45
Item 9a: Smoker ....................................................................................................... 46
Item 10a: PHQ.......................................................................................................... 47
Item 11a: Height ....................................................................................................... 48
Item 11b: Weight ...................................................................................................... 49
Item 11c: Waist......................................................................................................... 50
Item 12a: BPDate ..................................................................................................... 51
Item 12b: SBP .......................................................................................................... 52
Item 12c: DBP .......................................................................................................... 54
WISEWOMAN MDE Manual
Edition 18.3
iii
Item 13a: Fast .......................................................................................................... 56
Item 14a: TotChol ..................................................................................................... 57
Item 14b: HDL .......................................................................................................... 59
Item 14c: LDL ........................................................................................................... 61
Item 14d: Trigly......................................................................................................... 63
Item 15a: Glucose .................................................................................................... 65
Item 15b: A1C .......................................................................................................... 67
Item 16a: BPAlert ..................................................................................................... 68
Item 16b: BPDiDate .................................................................................................. 69
4. RISK REDUCTION COUNSELING MDE SPECIFICATIONS ............................................. 70
a. Summary of Risk Reduction Counseling MDEs ............................................................. 71
b. Risk Reduction Counseling MDE Specifications............................................................ 72
Item 17a: RRCComplete .......................................................................................... 72
5. HEALTHY BEHAVIOR SUPPORT SERVICES MDE SPECIFICATIONS ........................... 73
a. Summary of Healthy Behavior Support Services MDEs ................................................ 74
b. Healthy Behavior Support Services MDE Specifications ............................................... 75
Item 18a: RefDate .................................................................................................... 75
Item 19a: LSPHCRec ............................................................................................... 76
Item 19b: Intervention ............................................................................................... 77
Item 19c: LSPHCID .................................................................................................. 78
Item 20a: TobResDate ............................................................................................. 79
Item 20b: TobResType ............................................................................................. 80
Item 20c: TResComp................................................................................................ 81
APPENDIX A: SCREENING DEFINITIONS AND SUBMISSION GUIDANCE ....................... A.1
Data Submission Guidance................................................................................................A.1
Submission Procedures .....................................................................................................A.7
Data Confidentiality and Security .......................................................................................A.7
APPENDIX B: DATA QUALITY AND VALIDATION .............................................................. B.1
Validation of Data .............................................................................................................B.3
Data Validation Procedures and Forms..............................................................................B.4
Error Rate Calculation Method ...........................................................................................B.5
Validation of Data Form .....................................................................................................B.6
Participant ID Change Form...............................................................................................B.7
Correction to Previous MDE File Form ...............................................................................B.8
Supplemental Lifestyle Program and Health Coaching (LSP/HC) Session Spreadsheet .... B.9
APPENDIX C: DATA ANALYSIS AND USE .......................................................................... C.1
Data Summary Report Format and Content ...................................................................... C.3
Data Use by CDC ............................................................................................................ C.3
Potential Data Use by Funded Programs .......................................................................... C.3
APPENDIX D: TECHNICAL ASSISTANCE RESOURCES .................................................... D.1
Types of Technical Assistance Available .......................................................................... D.3
Helpdesk for Individualized Technical Assistance Requests ............................................. D.4
APPENDIX E: PERFORMANCE MEASURES ........................................................................E.1
APPENDIX F: NUTRITIONAL PROMPTS .............................................................................. F.1
WISEWOMAN MDE Manual
Edition 18.3
iv
1. INTRODUCTION
This WISEWOMAN MDE Manual was written to provide guidance on the collection and
submission of minimum data elements (MDEs) for the Well-Integrated Screening and
Evaluation for Women Across the Nation (WISEWOMAN) Program of the Centers for
Disease Control and Prevention (CDC). The Program currently funds recipients of the
cooperative agreement (“recipients”) across the United States to improve cardiovascular
health among low-income, underinsured, and uninsured women 40 to 64 years of age.
Recipients are required to collect and report MDEs as part of standardized data reporting for
the WISEWOMAN Program. 1 MDEs are used by CDC and its recipients to describe, monitor,
and assess progress and performance.
The MDEs in this manual (Edition 18.3) received approval in August 2019 from the Federal
Office of Management and Budget. This manual pertains to the cooperative agreement
DP18-1816. Data for the 59 MDEs can be separated into several categories: Administrative,
Screening and Assessment, Risk Reduction Counseling, and Healthy Behavior Support
Services.
The MDE manual includes information about technical specifications for the MDE variables
included in each of the categories, guidance for their submission, and conventions for
processing the data. Specifications for each MDE include variable name, definition, format,
source of data, denominator population, acceptable values, description, and use for data
analysis. Please note that the format provided is relevant for data submitted by
recipients for a six-month reporting period. Variables are reported for each participant.
These values for each participant establishes a record for their screening visit. The manual is
organized as follows:
•
Administrative MDE Specifications. This category includes 9 MDE variables. It
includes data about the recipient program, including its geography, provider sites,
aggregate screenings, and unique IDs of women to assess their health over time.
•
Screening and Assessment MDE Specifications. This category contains 42
required MDE variables. It includes data about participant demographics;
cardiovascular health status and history; clinical assessment values; and medical
treatment status.
•
Risk Reduction Counseling MDE Specifications. This category contains 1 required
MDE variable. It includes data about the risk reduction counseling received by
participants from a provider discussing their CVD risk.
•
Healthy Behavior Support Services MDE Specifications. This category contains 7
required MDE variables. It includes data about the evidence-informed Lifestyle
Program/Health Coaching sessions available and received by participants as well as
referrals to community-based tobacco cessation resources.
1 Throughout this document, capital “Program” refers to the CDC WISEWOMAN Program, and lower-case “program” refers
to the CDC-funded state/tribal recipients.
WISEWOMAN MDE Manual
Edition 18.3
1
•
Appendix A—MDE Screening Definitions and Submission Guidance. Data are
required to be submitted semiannually. This appendix details screening definitions and
submission guidance.
•
Appendix B—Data Quality and Validation. To promote high-quality, consistent data
across recipients, several tools are provided for use by recipients prior to MDE
submission and by CDC after submission. This appendix describes the various
validation procedures that recipients can use prior to submission and that CDC uses to
assess data quality. In addition, the method used to calculate the error rate is provided
for MDE submission files.
•
Appendix C—Data Analysis and Use. MDEs have several analytic purposes for
CDC and recipients, including (1) promoting public health practice through continuous
program improvement (2) measuring and improving program performance, (3)
assessing program health outcomes through evaluation and (4) calculating
Atherosclerotic Cardiovascular disease Risk (ASCVD). This appendix describes the
summary report format and the content produced and provided to recipients after each
submission. It also discusses use of the data by CDC as well as potential ways in
which recipients can utilize the data.
•
Appendix D—Technical Assistance Resources. Several technical assistance
resources are available to support recipients’ MDE data collection and reporting. This
appendix describes the various types of technical assistance resources that recipients
may access, including one-on-one technical assistance, group trainings, documents,
and tools available on the WISEWOMAN website. It also describes the process for
requesting individual technical assistance and the response process for CDC and the
data contractor.
•
Appendix E—Performance Measures. This appendix provides a list of the six
Program performance measures for DP18-1816.
•
Appendix F –Nutritional prompts. This appendix includes a supplemental handout
with examples for MDE items sourced from American Heart Association’s Life’s
Simple 7.
This manual is a living document that will be updated from time to time. When changes are
made to it, CDC will notify recipients that the updated manual is available on the
WISEWOMAN Data Management System website [https://wwwn.cdc.gov/wisewoman].
WISEWOMAN MDE Manual
Edition 18.3
2
2. ADMINISTRATIVE MDE SPECIFICATIONS
This section provides recipients with the information necessary to support collection and
reporting of administrative MDEs, which must be done according to the specifications
provided in this section of the manual.
These variables provide key contextual information about the structure and operations of
recipient programs and are essential to the services provided through the program. For each
participant record, programs provide FIPS/ANSI code in order to perform geospatial analyses
for public health purposes. In addition, for the six-month submission period recipients must
report for each participant the enrollment site, screening site, the type of screening received,
and unique participant ID. Missing or invalid values for these variables will be considered to
be errors.
This section begins with a summary of the 9 required variables (Subsection a) and then
provides the technical specifications for each variable (Subsection b).
WISEWOMAN MDE Manual
Edition 18.3
3
a. Summary of Administrative MDEs
Item
Number
1a
Variable Name
Beginning
Position
Variable Label
Type
StFIPS
1
State/Tribal FIPS code
1b
HdANSI
3
ANSI Geographic code (provider)
Character
1c
EnrollSiteID
8
Enrollment site ID
Character
1d
ScreenSiteID
13
Screening site ID
Numeric
2a
TimePer
23
Time period of screening
Numeric
2b
NScreen
24
Number of screenings received by the
participant
Numeric
2c
Type
25
Type of screening visit
Numeric
2d
Navigation
26
Were the navigation services paid for by
NBCCEDP funds, WISEWOMAN funds, Indian
Health Services/ Tribal funds, or other funds?
Numeric
3a
EncodeID
27
Unique participant ID number
Character
WISEWOMAN MDE Manual
Edition 18.3
4
Character
b. Administrative MDE Specifications
Item 1a: StFIPS*
State/Tribal FIPS Code
This variable indicates the FIPS or tribal program code for the state or tribe where the
administration of the program is located.
FORMAT
Type:
Character
Other Format:
N/A
Item Length:
2
Justification:
Left
Field Length:
2
Beginning Position:
1
Leading Zeros:
Yes
Valid Range:
Static Field:
Yes
See values; cannot be
blank
SOURCE
National FIPS Code List
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
National FIPS Code
ANALYSIS AND USE
To calculate the number of women screened by each state or tribal program
To assess the reach of the WISEWOMAN Program nationally and within a particular state or
tribe
Two-digit (character) value representing the identification of the
awardee that is providing services to the participant.
OTHER
INFORMATION
The state FIPS codes are the Federal Information Processing Standard codes developed by the
National Institute of Standards and Technology. The tribal program codes are codes assigned by
CDC to be used by tribal programs in lieu of FIPS.
Programs should always record the FIPS code for the state or tribe where their program is
located. This may differ from the FIPS code for the participant’s state or tribe of residence if the
participant resides in a state or tribe different from where the program is located. Any FIPS code
that is not the same as where the program is located will be flagged as an error.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
5
Item 1b: HdANSI*
ANSI Geographic Code (Provider)
This indicates the ANSI geographic code of the provider that conducts the WISEWOMAN
screening office visit.
FORMAT
Type:
Character
Other Format:
N/A
Item Length:
5
Justification:
Left
Field Length:
5
Beginning Position:
3
Leading Zeros:
Yes
Valid Range:
Valid ANSI code
Static Field:
No
SOURCE
National ANSI Code List, Census Bureau
DENOMINATOR
POPULATION
The denominator includes all screenings
VALUES AND
DESCRIPTION
ANSI Geographic Code
ANALYSIS AND USE
To assess whether programs and specific providers are meeting screening goals in targeted
geographic areas
To identify geographic areas where women have access to the WISEWOMAN Program
To provide information for geospatial analysis
To assist in identifying areas where there may be potential transportation barriers to accessing
WISEWOMAN services
Five-digit (character) value representing the geographic area of the
provider that conducts the screening office visit
OTHER
INFORMATION
ANSI codes are the American National Standards Institute codes, which were developed by the
American National Standards Institute. They are five-digit codes that represent states, counties,
and statistically equivalent areas, along with American Indian and Alaska Native areas.
The first two digits of the provider ANSI geographic code should represent the state of the
provider that conducts the screening office visit, and the last three digits should represent the
provider’s county.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
6
Item 1c: EnrollSiteID*
Enrollment Site ID
This variable indicates the site of a woman’s enrollment into the WISEWOMAN Program.
FORMAT
Type:
Character
Other Format:
N/A
Item Length:
5
Justification:
Left
Field Length:
5
Beginning Position:
8
Leading Zeros:
N/A
Valid Range:
Static Field:
Yes
Valid ZIP code; cannot be
blank
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Enrollment Site ID
ANALYSIS AND USE
To identify sites where outreach and enrollment are occurring
To identify sites where the Program is being administered and participants are tracked
To track the number of WISEWOMAN participants enrolled at each WISEWOMAN enrollment
site
Valid five-digit ZIP code for the location where the participant is
enrolled
OTHER
INFORMATION
The enrollment site ID should be the ZIP code of the location where the participant is enrolled.
This may be the ZIP code for a provider site location if a provider conducts enrollment, or the
ZIP code of the recipient location if the recipient conducts enrollment of the participant.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
7
Item 1d:
ScreenSiteID*
Screening Site ID
This variable indicates the site where a woman received her WISEWOMAN screening.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
10
Justification:
Right
Field Length:
10
Beginning Position:
13
Leading Zeros:
N/A
Valid Range:
Static Field:
No
Valid code for a screening
site; cannot be blank
SOURCE
National Provider Identifier
DENOMINATOR
POPULATION
The denominator includes all screenings
VALUES AND
DESCRIPTION
Screening Site ID
Value representing a National Provider Identifier for the provider
who conducts the screening office visit
ANALYSIS AND USE
To identify the geographic locations of sites providing screening services to participants
To track the number of WISEWOMAN participants screened at each WISEWOMAN screening
site
To describe differences in participant demographics or other characteristics by screening site
To provide information for geospatial analysis
To identify the number of screening providers in a given geographic area
To identify provider pool for assessment of health systems and providers that use clinical
systems of care successful in blood pressure control
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
8
Item 2a: TimePer*
Time Period of Screening
This variable indicates the 6-month time period of the screening for the participant.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
23
Leading Zeros:
No
Valid Range:
See values; cannot be blank
Static Field:
Yes
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all Complete/BP+ baseline screenings
VALUES AND
DESCRIPTION
1 6-month period 1
Screening took place between 09/30/18 and 03/31/19
2 6-month period 2
Screening took place between 04/01/19 and 09/29/19
3 6-month period 1
Screening took place between 09/30/19 and 03/31/20
4 6-month period 2
Screening took place between 04/01/20 and 09/29/20
5 6-month period 1
Screening took place between 09/30/20 and 03/31/21
6 6-month period 2
Screening took place between 04/01/21 and 09/29/21
7 6-month period 1
Screening took place between 09/30/21 and 03/31/22
8 6-month period 2
Screening took place between 04/01/22 and 09/29/22
9 6-month period 1
Screening took place between 09/30/22 and 03/31/23
0 6-month period 2
Screening took place between 04/01/23 and 09/29/23
ANALYSIS AND USE
To track the number of screenings for each participant.
OTHER
Time period of screening should be provided for each participant screening.
INFORMATION
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
9
Item 2b: NScreen*
Number of Screenings Received by the Participant
This variable indicates the total number of screenings that the participant has received since the
beginning of the cooperative agreement.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
24
Leading Zeros:
No
Valid Range:
Cannot be blank
Static Field:
No
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Number of Visits
ANALYSIS AND USE
To track the number of screenings/ follow-up screenings/rescreenings
Value representing the number of screenings that the participant has
received since the beginning of this cooperative agreement (includes
current screening).
Any values outside 1 to 8 will be flagged for a quality check
OTHER
This field should include the number of screenings that the participant has received since the
INFORMATION
beginning of the cooperative agreement.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
10
Item 2c: Type*
Type of Screening Visit
This variable indicates whether the record represents a baseline screening visit, a rescreening
visit, or a post-Lifestyle Program (LSP)/Health Coaching (HC) follow-up screening.
FORMAT
Type:
Numeric
Other Format:
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
25
Leading Zeros:
No
Valid Range:
See values; cannot be blank
Static Field:
No
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all screenings
VALUES AND
DESCRIPTION
ANALYSIS AND USE
N/A
1
Screening
Record represents a baseline screening visit
2
Rescreening
Record represents a rescreening visit
3
Follow-up screening –
LSP/HC complete
Record represents a 4 to 6 week post-LSP/HC follow-up
screening with a complete LSP/HC
4
Follow-up screening –
LSP/HC incomplete
Record represents a 4 to 6 week post-LSP/HC follow-up
screening with an incomplete LSP/HC
9
No answer recorded
No answer recorded
This value will be flagged as an error
To assess the number of unique women served by the WISEWOMAN Program
To track participants screening values over time
To link baseline screenings with rescreenings
To assess participants progress after completion of an LSP/HC
OTHER
INFORMATION
Baseline screenings, rescreenings, and follow-up screenings will be classified as complete,
blood pressure plus (BP+), or incomplete based on the definitions in Appendix A.
Rescreenings occur between 11 and 18 months following the previous screening/rescreening.
Follow-up screenings occur between 3 and no later than 11 months after the previous baseline
screening/ rescreening and within 4 to 6 weeks after LSP/HC completion.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
11
Item 2d: Navigation*
Were the navigation services paid for by NBCCEDP funds, WISEWOMAN funds, Indian
Health Services/ Tribal funds, or other funds?
This variable indicates the funding source for navigation services for participants who receive
healthy behavior support services, but whose cardiovascular screenings are not funded by
WISEWOMAN.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
26
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all screenings
VALUES AND
DESCRIPTION
1
NBCCEDP funds
Funding source for navigation services was paid by NBCCEDP
funds
2
WISEWOMAN funds
Funding source for navigation services was paid by
WISEWOMAN funds
3
Indian Health
Service/Tribal funds
Funding source for navigation services was paid by Indian Health
Services/ Tribal funds
4
Other funds
Funding source for navigation services was paid by other funds
5
Not Applicable
Not applicable
ANALYSIS AND USE
To track funding sources for navigation services for participants who receive healthy behavior
support services through the federally-funded WISEWOMAN program
OTHER
INFORMATION
WISEWOMAN participants who receive healthy behavior support services (such as health
coaching or lifestyle programs), but whose cardiovascular screenings are reimbursed through
an alternative payment source other than WISEWOMAN are considered navigated.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
12
Item 3a: EncodeID*
Unique Participant ID Number
This variable indicates a woman’s unique identification number.
FORMAT
Type:
Character
Other Format:
N/A
Item Length:
15
Justification:
Left
Field Length:
15
Beginning Position:
27
Leading Zeros:
N/A
Valid Range:
Cannot be blank
Static Field:
Yes
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Unique Participant ID
Number
ANALYSIS AND USE
To assess the number of unique women served by the WISEWOMAN Program
To track participants over time
To link baseline screenings with rescreenings
To link screenings with risk reduction counseling, lifestyle programs, health coaching, and
community-based resource referrals
OTHER
INFORMATION
A participant’s unique ID should not change over time. If it does change, the program should
provide the data contractor and Project Officer with a list of IDs that have changed at the time of
data submission and upload a crosswalk of the previous participant unique IDs to the new
participant unique IDs (see Appendix B).
Value representing the unique identifier for a participant
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
13
3. SCREENING AND ASSESSMENT MDE SPECIFICATIONS
The purpose of this section is to provide recipients with the information necessary to support
collection and reporting of Screening and Assessment MDEs, which must be done according
to the specifications provided in this section of the manual. Complete and BP+ records are
determined by MDEs provided under the Screening and Assessment category. Complete
records will be used to calculate Atherosclerotic Cardiovascular Disease (ASCVD) risk,
conduct detailed outcome analyses on CVD risk factors, and measure program
implementation. BP+ records only meet the minimum requirements to measure ASCVD risk.
For a record to be counted as a Complete or BP+ screening, it must have valid values for
required MDEs. Definitions of complete and BP+ screenings are provided in Appendix
A.
Recipients are required to report all records, including those records that do not meet
screening requirements, and they will be used to account for WISEWOMAN resources, but
will not be analyzed in MDE reports generated by CDC or counted toward screening goals
unless additional documentation is provided. 2,3
Below is a summary of the 42 required variables in the Screening and Assessment file
(Subsection a). After the summary, the technical specifications for each variable are provided
(Subsection b).
2 Screening goals are agreed upon between each recipient and CDC. The number of screenings used to assess progress
toward meeting the screening goal is calculated as the number of records meeting minimum screening requirements
(baseline, follow-up screening or rescreening).
3 If the program is unable to obtain or the participant refuses to allow measurements for height, weight, blood pressure
reading, labs, or to complete the personal assessment history, the program may choose to submit an explanation for this
situation to be considered as an acceptable screening record. See Appendix B for additional information on this process.
WISEWOMAN MDE Manual
Edition 18.3
14
a. Summary of Screening and Assessment MDEs
Item
Number
Variable
Name
Beginning
Position
Variable Label
Type
3b
ResANSI
42
ANSI geographic code of residence
Character
3c
ZIP
47
ZIP code of residence
Character
3d
MYB
52
Month and year of birth
Numeric
3e
Latino
58
Hispanic or Latino origin
Numeric
3f
Race1
59
Race: first race
Numeric
3g
Race2
60
Race: second race
Numeric
3h
Education
61
Education (highest grade completed)
Numeric
3i
Language
62
What is the primary language spoken in your home?
Numeric
4a
SRC
64
Which of the following conditions do you have: i.
Hypertension, ii High cholesterol, iii Diabetes (Type 1
or Type 2)
Numeric
4b
SRHA
67
Have you had any of the following: i. Stroke/
transient ischemic attack (TIA), ii. Heart attack, iii.
Coronary heart disease, iv Heart failure, v. Vascular
disease (peripheral arterial disease), vi. Congenital
heart disease and defects
Numeric
5a
Meds
73
Was medication prescribed to lower: i. Blood
pressure, ii. Cholesterol (Statin), iii. Cholesterol
(other prescribed medication), iv. Blood sugar
Numeric
5b
Aspirin
77
Are you taking aspirin daily to help prevent a heart
attack or stroke?
Numeric
5c
MedAdhere
78
During the past 7 days, how many days did you take
prescribed medication for the following conditions: i.
High blood pressure (0 – 7 days), ii. High cholesterol
(0 – 7 days), iii. High blood sugar (0 – 7 days)
Numeric
5d
Monitored
84
After being prescribed medication, on what date(s)
did the participant have her blood pressure remeasured either by a healthcare provider, or with
another community resource?
Numeric
6a
BPHome
108
Do you measure your blood pressure at home or
using other calibrated sources?
Numeric
6b
BPFreq
109
How often do you measure your blood pressure at
home or using other calibrated sources?
Numeric
6c
BPSend
110
Do you regularly share blood pressure readings with
a health care provider for feedback?
Numeric
7a
FruitVeg
111
How many cups of fruits and vegetables do you eat
in an average day?
Numeric
7b
Fish
113
Do you eat fish at least two times a week?
Numeric
7c
Grains
114
Thinking about all the servings of grain products you
eat in a typical day, how many are whole grains?
Numeric
7d
Sugar
115
Do you drink less than 36 ounces (450 calories) of
beverages with added sugars weekly?
Numeric
7e
SaltWatch
116
Are you currently watching or reducing your sodium
or salt intake?
Numeric
7f
AlcFreq
117
In the past 7 days, how often do you have a drink
containing alcohol?
Numeric
7g
AlcDay
119
How many alcoholic drinks, on average, do you
consume during a day you drink?
Numeric
8a
PA
121
How many minutes of physical activity (exercise) do
you get in a week?
Numeric
WISEWOMAN MDE Manual
Edition 18.3
15
Item
Number
Variable
Name
Beginning
Position
Variable Label
Type
9a
Smoker
125
Do you smoke? Includes cigarettes, pipes, or cigars
(smoked tobacco in any form)
Numeric
10a
PHQ
126
Over the past 2 weeks, how often have you been
bothered by any of the following problems?
i. Little interest or pleasure in doing things (not at
all, several days, more than half, or nearly every
day)?
ii. Feeling down, depressed, or hopeless (not at all,
several days, more than half, or nearly every
day)?
Numeric
11a
Height
128
Height, inches
Numeric
11b
Weight
130
Weight, pounds
Numeric
11c
Waist
133
Waist circumference, inches
Numeric
12a
BPDate
135
Clinical assessment date (office visit date)
Numeric
12b
SBP
143
Systolic blood pressure, mmHg
Numeric
12c
DBP
155
Diastolic blood pressure, mmHg
Numeric
13a
Fast
167
Fasting status
Numeric
14a
TotChol
168
Total cholesterol (fasting or nonfasting), mg/dL
Numeric
14b
HDL
171
HDL cholesterol (fasting or nonfasting), mg/dL
Numeric
14c
LDL
174
LDL cholesterol (fasting or nonfasting), mg/dL
Numeric
14d
Trigly
177
Triglycerides (fasting or nonfasting), mg/dL
Numeric
15a
Glucose
181
Glucose (fasting only), mg/dL
Numeric
15c
A1C
184
A1C percentage
Numeric
16a
BPAlert
188
Is a medical follow-up for blood pressure reading
necessary?
Numeric
16b
BPDiDate
189
What is the date of the medically necessary followup appointment?
Numeric
WISEWOMAN MDE Manual
Edition 18.3
16
b. Screening and Assessment MDE Specifications
Item 3b: ResANSI*
ANSI Geographic Code of Residence
This variable indicates the ANSI geographic code of residence of the WISEWOMAN participant.
FORMAT
Type:
Character
Other Format:
N/A
Item Length:
5
Justification:
Left
Field Length:
5
Beginning Position:
42
Leading Zeros:
Yes
Valid Range:
Static Field:
No
Valid ANSI code;
cannot be blank
SOURCE
National ANSI Code List
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
ANSI Geographic Code
ANALYSIS AND USE
To assess whether programs are meeting screening goals in targeted geographic areas
To identify the reach of the WISEWOMAN Program
To assist in identifying areas where there may be potential transportation barriers to accessing
WISEWOMAN services
Value representing the participant’s geographic area of residence
OTHER
INFORMATION
ANSI codes are the American National Standards Institute codes, which were developed by the
American National Standards Institute. They are five-digit codes that represent states, counties,
and statistically equivalent areas, along with American Indian and Alaska Native areas.
The first two digits of the participant ANSI geographic code of residence should represent the
state of residence for the participant, and the last three digits should represent the participant’s
county of residence.
Both ANSI geographic area of residence and ZIP code of residence (3c: ZIP) are required. ZIP
code of residence should correspond to the ANSI geographic code of residence, in that the ZIP
code must represent a valid geographic area within the county.
If a participant does not reside in the state where the program is located, the ANSI code from
her actual state of residence should be recorded.
ANSI geographic code of residence should be captured at the first screening visit of the
submission period; if geographic code of residence changes during a submission period, the
last code collected for the submission period should be recorded.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
17
Item 3c: ZIP*
ZIP Code of Residence
This variable indicates the participant’s ZIP code of residence.
FORMAT
Type:
Character
Other Format:
N/A
Item Length:
5
Justification:
Left
Field Length:
5
Beginning Position:
47
Leading Zeros:
Yes
Valid Range:
Static Field:
No
Valid Zip code;
cannot be blank
SOURCE
National ZIP Code List
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
ZIP Code of Residence
Valid five-digit (character) ZIP code
99999a
No ZIP code recorded
This value will be flagged as an error
ANALYSIS AND USE
To assess whether programs are meeting screening goals in targeted geographic areas
To identify the reach of the WISEWOMAN Program
To identify participant county of residence outside program state boundaries
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Both ANSI geographic code of residence (3b: ResANSI) and ZIP code of residence are
required. ZIP code of residence should correspond to the county code of residence, in that the
ZIP code must represent a valid geographic area within the county.
ZIP code of residence must be recorded regardless of whether or not the woman resides in the
same state as the program. This information will be used in conjunction with geographic code of
residence to identify the area of residence for a woman.
If a participant does not reside in the same state as the program, the ZIP code from her actual
state of residence should be recorded.
ZIP code of residence should be captured at the first screening visit of the submission period; if
ZIP code of residence changes during a submission period, the last code collected for the
submission period should be recorded.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
18
Item 3d: MYB*
Month and Year of Birth
This variable indicates the participant’s month and year of birth.
FORMAT
Type:
Numeric
Other Format:
MMCCYY date
Item Length:
6
Justification:
Right
Field Length:
6
Beginning Position:
52
Leading Zeros:
Yes
Valid Range:
Static Field:
Yes
Valid date; cannot be
blank
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Month and Year of Birth
ANALYSIS AND USE
To estimate the age of the participant; age will be calculated using the month and year of birth
and office visit date (BPDate)
To assist in characterizing the population reached by the WISEWOMAN Program
To provide data element required to determine participant’s cardiovascular risk or risk score
To assess whether the participants are within the Program’s priority age group
OTHER
INFORMATION
Month and Year of Birth in MMCCYY format
Example: September 01, 1965 = 091965
The priority population for the WISEWOMAN Program is women aged 40 to 64. Services
provided to women outside the priority age range will be monitored by CDC.
Month and year of birth at screening is required for a record to count as a complete or BP+
record. If MYB is blank, the record will not count as a complete or BP+ record, and the record
will not count toward meeting a program’s screening goal.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
19
Item 3e: Latino*
Hispanic or Latino Origin
This variable indicates whether the participant is of Hispanic or Latino origin.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
58
Leading Zeros:
No
Valid Range:
Static Field:
Yes
See values; cannot
be blank
SOURCE
United States Office of Management and Budget Guidelines
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
Yes
Participant reports that she is of Hispanic or Latino origin
2
No
Participant reports that she is not of Hispanic or Latino origin
7
Unknown
9
ANALYSIS AND USE
No answer
Participant is unsure whether she is of Hispanic or Latino origin
recordeda
Participant has not reported whether she is of Hispanic or Latino
origin
This value will be flagged as an error
To assess the race/ethnicity of WISEWOMAN participants
To analyze screening, lifestyle programs, and other variables by ethnicity
To assist in characterizing the population reached by the WISEWOMAN Program
To provide data element required to determine participant’s cardiovascular risk or risk score
aCodes and response options highlighted in gray should not appear on the data collection forms
OTHER
INFORMATION
presented to participants. They are provided for funded program use only.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
20
Item 3f: Race1*
Race: First Race
This variable indicates a race with which the participant identifies.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
59
Leading Zeros:
No
Valid Range:
Static Field:
Yes
See values; cannot
be blank
SOURCE
United States Census Bureau; United States Office of Management and Budget Guidelines
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
White
Participant identifies White as a race
2
Black or African
American
Participant identifies Black or African American as a race
3
Asian
Participant identifies Asian as a race
4
Native Hawaiian or
Other Pacific
Islander
Participant identifies Native Hawaiian or Other Pacific Islander as
a race
5
American Indian or
Alaska Native
Participant identifies American Indian or Alaska Native as a race
7
Unknown
Participant does not know her race or does not identify with any of
the races listed above
If a participant is Hispanic and does not identify a race, this code
should be used
9
No answer recordeda
Race information is missing for the participant
Any race information gathered should be entered beginning with
the Race1 field
ANALYSIS AND USE
To assess the race/ethnicity of WISEWOMAN participants
To understand and analyze screening, lifestyle programs, and other variables by race
To assist in characterizing the population reached by the WISEWOMAN Program
To provide data element required to determine participant’s cardiovascular risk or risk score
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
If a participant identifies more than one race, one race is recorded here and other race she
identifies is recorded in the subsequent race field (3g: Race2).
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
21
Item 3g: Race2
Race: Second Race
This variable indicates a race with which the participant identifies in cases where a participant is
multiracial.
FORMAT
Type:
Numeric
Other Format:
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
60
Leading Zeros:
No
Valid Range:
Static Field:
Yes
See values; cannot
be blank
N/A
SOURCE
United States Census Bureau; United States Office of Management and Budget Guidelines
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
White
Participant identifies White as a race
Participant who has identified two or more races can have this
value
2
Black or African
American
Participant identifies Black or African American as a race
Participant who has identified two or more races can have this
value
3
Asian
Participant identifies Asian as a race
Participant who has identified two or more races can have this
value
4
Native Hawaiian or
Other Pacific Islander
Participant identifies Native Hawaiian or Other Pacific Islander as
a race
Participant who has identified two or more races can have this
value
5
American Indian or
Alaska Native
Participant identifies American Indian or Alaska Native as a race
Participant who has identified two or more races can have this
value
7
Unknown
Participant does not know her race or does not identify with any of
the races listed above
9
No answer recordeda
If race information is missing for Race2
Participant has not identified any race
Participant has identified one race and does not identify other
races
If a participant does not identify a second race, ‘9 No answer
recorded’ should be used for this field and all subsequent race
fields
ANALYSIS AND USE
To assess the race/ethnicity of WISEWOMAN participants
To understand and analyze screening, lifestyle programs, and other variables by race
To assist in characterizing the population reached by the WISEWOMAN Program
To provide data element required to determine participant’s cardiovascular risk or risk score
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
If a participant identifies two races, one race is recorded in Race1 and a second race is recorded
here.
WISEWOMAN MDE Manual
Edition 18.3
22
Item 3h: Education
Education (highest grade completed)
This variable indicates the highest grade the participant completed.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
61
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot
be blank
SOURCE
CDC Behavioral Risk Factor Surveillance System
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
<9th grade
Participant reports that she did not attend high school
2
Some high school
Participant reports she attended high school, but did not graduate
3
High school graduate
or equivalent
Participant reports that she graduated from high school or has
the equivalent of a high school diploma, and she did not attend
any college or higher education
4
Some college or
higher
Participant reports that she attended one or more years of
college and/or graduate school (e.g., college graduate, graduate
degree)
7
Don’t know/Not sure
Participant reports that she does not know the highest grade she
completed
This value will be flagged as a quality check
8
Don’t want to answera
Participant does not want to answer the highest grade she
completed
This value will be flagged as a quality check
9
No answer recordeda
Education information is missing for the participant
This value will be flagged as an error
ANALYSIS AND USE
To assess the educational attainment of women in the WISEWOMAN population
To understand screening, lifestyle programs , and other variables by education status
To help determine the literacy level needed for materials developed for recruitment, risk
reduction counseling, lifestyle programs, health coaching, and community-based resources
To assist in characterizing the population reached by the WISEWOMAN Program
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
WISEWOMAN MDE Manual
Edition 18.3
23
Item 3i: Language
What is the primary language spoken in your home?
This variable indicates the primary language spoken in the participant’s home.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
2
Justification:
Right
Field Length:
2
Beginning Position:
62
Leading Zeros:
Yes
Valid Range:
Static Field:
Yes
See values; cannot
be blank
SOURCE
National Survey of Children’s Health
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
01 English
Participant identifies English as the primary language spoken in
her home
02 Spanish
Participant identifies Spanish as the primary language spoken in
her home
03 Arabic
Participant identifies Arabic as the primary language spoken in
her home
04 Chinese
Participant identifies Chinese as the primary language spoken in
her home
05 French
Participant identifies French as the primary language spoken in
her home
06 Italian
Participant identifies Italian as the primary language spoken in
her home
07 Japanese
Participant identifies Japanese as the primary language spoken
in her home
08 Korean
Participant identifies Korean as the primary language spoken in
her home
09 Polish
Participant identifies Polish as the primary language spoken in
her home
10 Russian
Participant identifies Russian as the primary language spoken in
her home
11 Tagalog
Participant identifies Tagalog as the primary language spoken in
her home
12 Vietnamese
Participant identifies Vietnamese as the primary language
spoken in her home
13 Creole
Participant identifies Creole as the primary language spoken in
her home
14 Portuguese
Participant identifies Portuguese as the primary language
spoken in her home
15 Hmong
Participant identifies Hmong as the primary language spoken in
her home
16 Other Language
Participant identifies another language as the primary language
spoken in her home (write-in response)
88 Don’t want to answera
Participant does not want to answer the primary language
spoken in her home
This value will be flagged as a quality check
99 No answer recordeda
Primary language information is missing for the participant
This value will be flagged as an error
WISEWOMAN MDE Manual
Edition 18.3
24
ANALYSIS AND USE
To assess the primary language of women in the WISEWOMAN population
To provide context to potential the health literacy issues
To assist in characterizing the population reached by the WISEWOMAN Program
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
WISEWOMAN MDE Manual
Edition 18.3
25
Item 4a: SRC*
Which of the following conditions do you have:
i.
Hypertension
ii.
High cholesterol
iii.
Diabetes (Type 1 or Type 2)
This variable indicates whether the participant has hypertension, high cholesterol, and/ or
diabetes.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
3
Justification:
Right
Field Length:
3
Beginning Position:
64
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be blank if
TYPE is 1, 2, 3 or 4 (baseline
screening, rescreening or follow-up)
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
(CODE FOR EACH
CONDITION)
1
Yes
Participant has the condition
2
No
Participant does not have the condition
7
Don’t know/Not sure
Participant does not know whether she has condition
This value will be flagged as a quality check
8
Don’t want to answera
Participant does not want to answer whether she has the
condition
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To understand the cardiovascular disease risk factors of individual participants and the overall
WISEWOMAN population
To assess the number of cases of hypertension, high cholesterol, and diabetes that have been
previously diagnosed as opposed to newly detected cases among the WISEWOMAN population
To assess control of and improvements in blood pressure, cholesterol, and diabetes for newly
and previously diagnosed women
To provide data elements required to determine participant’s cardiovascular risk score
OTHER
INFORMATION
Guidance
aCodes and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Each of the three positions in the SRC field corresponds to a specific condition. The first position
aligns with the participant’s hypertension history. The second position aligns with the
participant’s high cholesterol history. The third position aligns with the participant’s diabetes
history.
Programs should assess a participant’s history for each condition and record the corresponding
value in the appropriate position in the SRC field. For example, if a participant reports that she:
(a) has hypertension, (b) does not have high cholesterol, and (c) is unsure whether she has
diabetes, SRC should be recorded as ‘127’ (corresponding to values of ‘1- Yes’ in position 1, ‘2 –
No’ in position 2, and ‘7 – Don’t know/ not sure’ in position 3).
Some programs may have access to participants’ medical charts. In some cases, the medical
chart may show that a participant’s diagnosis for hypertension, high blood cholesterol, and/or
diabetes is inconsistent with her self-report. In these instances, if the medical record indicates
that she has hypertension, high blood cholesterol, and/or diabetes, the program should recode
the relevant position of SRC as ‘1 Yes.’
Hypertension, cholesterol, and diabetes history status is required for a record to count as
complete or BP+. If any position of SRC is blank or coded as ‘‘9 No answer recorded,’ the record
will not count as a complete or BP+ record, and the record will not count toward meeting a
program’s screening goal.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
26
Item 4b: SRHA*
Have you had any of the following:
i.
Stroke/ transient ischemic attack (TIA)
ii.
Heart attack
iii.
Coronary heart disease
iv.
Heart failure
v.
Vascular disease (peripheral arterial disease)
vi.
Congenital heart disease and defects
This variable indicates whether the participant has ever been diagnosed by a healthcare provider
as having stroke/ TIA, heart attack, coronary heart disease, heart failure, vascular disease
(peripheral arterial disease), and/ or congenital heart disease and defects.
FORMAT
Type:
Numeric
Item Length:
Other Format:
N/A
6
Justification:
Right
Field Length:
6
Beginning Position:
67
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be blank if
TYPE is 1, 2, 3 or 4 (baseline
screening, rescreening or follow-up)
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
(CODE FOR EACH
CONDITION)
1
Yes
Participant has been diagnosed by a healthcare provider as
having the condition
2
No
Participant has never been diagnosed by a healthcare provider
as having each condition
7
Don’t know/Not sure
Participant does not know whether she has been diagnosed by a
healthcare provider as having the condition
This value will be flagged as a quality check
8
Don’t want to answera
Participant does not want to answer whether she has been
diagnosed by a healthcare provider as having the condition
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To understand the history of cardiovascular disease among individual participants and the
overall WISEWOMAN population
To assess the number of participants who have been previously diagnosed as having
cardiovascular disease
To provide data elements required to determine participant’s cardiovascular risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Each of the six positions in the SRHA field corresponds to a specific condition. The first position
aligns with the participant’s history of stroke/ TIA. The second position aligns with the
participant’s history of heart attack. The third position aligns with the participant’s history of
coronary heart disease. The fourth position aligns with the participant’s history of heart failure.
The fifth position aligns with the participant’s history of vascular disease. The sixth position aligns
with the participant’s history of congenital heart disease and defects.
Programs should assess a participant’s history for each condition and record the corresponding
value in the appropriate position in the SRHA field. For example, if a participant reports that she
had a stroke, but did not have heart attack, coronary heart disease, heart failure, vascular
disease (peripheral arterial disease), or congenital heart disease and defects, SRHA should be
recorded as ‘122222’ (corresponding to values of ‘1- Yes’ in position 1 and ‘2 – No’ in position 2
through position 6).
WISEWOMAN MDE Manual
Edition 18.3
27
OTHER
INFORMATION
(CONT.)
Some programs may have access to participants’ medical charts. In some cases, the medical
chart may show that a participant’s diagnosis for one of the specified conditions is inconsistent
with her self-report. In these instances, if the medical record indicates that she has had any one
of these conditions, the program should recode the corresponding position of SRHA as ‘1 Yes.’
History of each of the six conditions is required for a record to count as a complete or BP+
record. If any position of SRHA is blank or coded as ‘’9 No answer recorded,’ the record will not
count as a complete or BP+ record, and the record will not count toward meeting a program’s
screening goal.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
28
Item 5a: Meds*
Was medication prescribed to lower:
i.
Blood pressure
ii.
Cholesterol (Statin)
iii.
Cholesterol (other prescribed medication)
iv.
Blood sugar
This variable indicates whether the participant was prescribed medication to lower her blood
pressure, cholesterol, and/or blood sugar.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
4
Justification:
Right
Field Length:
4
Beginning Position:
73
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot
be blank
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes WISEWOMAN participants with hypertension (high blood pressure),
high cholesterol, or diabetes or participants who were previously diagnosed with hypertension
(high blood pressure), high cholesterol, or diabetes
VALUES AND
DESCRIPTION
(CODE FOR EACH
CONDITION)
1
Yes
2
No
Participant was prescribed medication for the condition
Participant was not prescribed medication for the condition
Applicablea
5
Not
7
Don’t know/Not sure
Participant does not know whether she was prescribed
medication for the condition
This value will be flagged as a quality check
8
Don’t want to answera
Participant does not want to answer whether she was prescribed
medication for the condition
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
This question is not applicable for the patient because she has
never been diagnosed with for the condition, either because she
does not have for the condition (as assessed with a
measurement at screening/ rescreening) or because she reports
that she has never been diagnosed with for the condition (as
assessed with self-report at screening/ rescreening).
ANALYSIS AND USE
To understand the cardiovascular disease risk factors of individual participants and the overall
WISEWOMAN population
To assess the number of cases of hypertension, high cholesterol, and diabetes that have been
previously diagnosed as opposed to newly detected cases among the WISEWOMAN population
To assess the control and management of blood pressure, cholesterol, and diabetes among
participants who have hypertension, high cholesterol, or diabetes
To assist in assessment of adherence to medication for hypertension, high cholesterol, and
diabetes
To provide data element required to determine participant’s ASCVD risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Each of the four positions in the Meds field corresponds to use of a condition-specific type of
medication. The first position aligns with use of blood pressure medication. The second position
aligns with use of statins for high cholesterol. The third position aligns with use of other
medication (besides statins) for high cholesterol. The fourth position aligns with use of
medication for diabetes.
WISEWOMAN MDE Manual
Edition 18.3
29
OTHER
INFORMATION
(CONT.)
Programs should assess a participant’s prescribed medication status for each condition and
record the corresponding value in the appropriate position in the Meds field. For example, if a
participant reports that she: (a) has hypertension and is not prescribed blood pressure
medication, (b) does not have high cholesterol and was not prescribed statins, (c) does not
have high cholesterol and was not prescribed other cholesterol medication, and (d) has
diabetes and was prescribed blood sugar medication, Meds should be recorded as ‘2551’
(corresponding to values of ‘2 – No’ in position 1, ‘5 – Not applicable’ in position 2, ‘5 – Not
applicable’ in position 3, and ‘1 – Yes’ in position 4).
If a participant reports that she doesn’t know whether she was prescribed medication for one of
these conditions or doesn’t want to answer whether she was prescribed medication for one of
these conditions, programs should have a discussion with her to verify the response.
Medication prescription status at screening is required for a record to count as a complete or
BP+ record. If Meds is blank or coded as ‘‘9 No answer recorded,’ the record will not count as a
complete or BP+ record, which means the record will not count toward meeting a program’s
screening goal.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
30
Item 5b: Aspirin*
Are you taking aspirin daily to help prevent a heart attack or stroke?
This variable indicates whether the participant is taking aspirin daily to help prevent a heart
attack or stroke.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
77
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
American College of Cardiology
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
Yes
Participant is taking aspirin daily to help prevent a heart attack or
stroke
2
No
Participant is not taking aspirin daily to help prevent a heart
attack or stroke
7
Don’t know/Not sure
Participant does not know whether she is taking aspirin daily to
help prevent a heart attack or stroke
This value will be flagged as a quality check
8
Don’t want to answera
Participant does not want to answer whether she is taking aspirin
daily to help prevent a heart attack or stroke
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To understand the cardiovascular disease risk factors of individual participants and the overall
WISEWOMAN population
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
If a participant reports that she doesn’t know whether she is taking aspirin or doesn’t want to
answer whether she is taking aspirin, programs should have a discussion with her to verify the
response.
Use of aspirin at screening is required for a record to count as a complete or BP+ record. If
Aspirin is blank or coded as ‘‘9 No answer recorded,’ the record will not count as a complete or
BP+ record, which means the record will not count toward meeting a program’s screening goal.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
31
Item 5c: MedAdhere*
During the past 7 days, how many days did you take prescribed medication for the
following conditions:
i.
High blood pressure (0 – 7 days)
ii.
High cholesterol (0 – 7 days)
iii.
High blood sugar (0 – 7 days)
This variable indicates the number of days out of the past 7 days, including the day of the
screening, that the participant took prescribed medication to lower her blood pressure,
cholesterol, and/or blood sugar.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
6
Justification:
Right
Field Length:
6
Beginning Position:
78
Leading Zeros:
Yes
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
Adapted from National Survey of Children’s Health
DENOMINATOR
POPULATION
The denominator includes WISEWOMAN participants taking medication to lower blood
pressure, cholesterol, or blood sugar
VALUES AND
DESCRIPTION
(CODE FOR EACH
CONDITION)
Number of days (01-07)
A numeric value indicating the number of days out of the past 7
days, including the day of the screening, that the participant took
prescribed medication for the condition
Any value outside the valid range (01 – 07) will be considered an
error
00 None
In the past 7 days, including the day of the screening, the
participant did not take prescribed medication for the condition
55 Not Applicablea
This question is not applicable for the patient because she has
never been diagnosed with the condition (high blood pressure,
high cholesterol, or high blood sugar) and/or has indicated that
she does not take medication for the condition
77 Don’t know/Not sure
Participant is not sure whether she took prescribed medication to
lower her cholesterol during the past 7 days including the day of
the screening
This value will be flagged as a quality check
88 Don’t want to answera
Participant did not want to answer whether she took prescribed
medication for the condition during the past 7 days, including the
day of the screening
This value will be flagged as a quality check
99 No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To facilitate assessment of adherence to medication prescribed for high blood pressure, high
cholesterol, and diabetes
To assist in determining management and control for high blood pressure, high cholesterol, and
diabetes
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Each of the three positions in the MedAdhere field corresponds with the number of days taking
medication for a specific condition in the past week. The first position aligns with the number of
days taking medication for hypertension. The second position aligns with the number of days
taking medication for high cholesterol. The third position aligns with the number of days taking
medication for high blood sugar.
WISEWOMAN MDE Manual
Edition 18.3
32
OTHER
INFORMATION
(CONT.)
Programs should assess the number of days a participant took prescribed medication for each
condition and record the corresponding value in the appropriate position of 5c: MedAdhere. For
example, if a participant reports that she: (a) has never been diagnosed with hypertension and
has not been prescribed blood pressure medication, (b) was prescribed medication for high
cholesterol and takes medication 7 day per week, and (c) has diabetes and was prescribed
medication for blood sugar, but does not take this medication ever, MedAdhere should be
recorded as ‘550700’ (corresponding to values of ‘55 – Not applicable’ in position 1, ‘07 – 7
days per week’ in position 2, and ‘00 – None’ in position 3).
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
33
Item 5d: Monitored
After being prescribed medication, on what date(s) did the participant have her blood
pressure re-measured either by a healthcare provider, or with another community
resource?
This variable indicates the date when blood pressure is re-measured for a participant who is
prescribed blood pressure medication, which is often related to titration of prescribed blood
pressure medications.
FORMAT
Type:
Numeric
Other Format:
MMDDCCYY
Item Length:
8
Justification:
Right
Field Length:
24
Beginning Position:
84
Leading Zeros:
Yes
Valid Range:
Valid date
Static Field:
No
SOURCE
WISEWOMAN-specific optional variable for blood pressure follow-up
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants taking medication to lower blood
pressure
VALUES AND
DESCRIPTION
Blood Pressure
Monitoring Dates
ANALYSIS AND USE
To assist in determining management and control for high blood pressure
OTHER
INFORMATION
This is an optional recipient use field. If systolic blood pressure re-measurements are
recorded in 12b: SBP (positions 4 through 12) or diastolic blood pressure re-measurements are
recorded in 12c: DBP (positions 4 through 12), programs should document the date of the blood
pressure re-measurement in the Monitored field.
The position of the re-measurement date in Monitored should correspond with the position of
the blood pressure re-measurement in SBP and DBP. For example, the first systolic blood
pressure re-measurement should be entered in positions 4 through 6 of SBP, the first diastolic
blood pressure re-measurement should be entered in positions 4 through 6 of DBP, and the
date of the first blood pressure re-measurement should be recorded in positions 1 through 8 of
Monitored. If another re-measurement is obtained after the screening date and prior to a
subsequent follow-up screening or rescreening, the second systolic blood pressure remeasurement should be recorded in positions 7 through 9 of SBP, the second diastolic blood
pressure re-measurement should be recorded in position 7 through 9 of DBP, and the remeasurement date associated with the second blood pressure re-measurement should be
recorded in position 9 through 16 of Monitored.
Programs can submit up to three blood pressure re-measurements and re-measurement dates.
If one or more SBP re-measurements or DBP re-measurements are recorded then a date must
accompany it in Monitored (MDE 5d).
WISEWOMAN MDE Manual
Edition 18.3
Valid date in MMDDCCYY format
Date when blood pressure is re-measured by a health care
provider or another community resource
Example: September 10, 2018 = 09102018
34
Item 6a: BPHome
FORMAT
Do you measure your blood pressure at home or using other calibrated sources?
This variable indicates whether the participant monitors her blood pressure at home or using
other calibrated sources (select the best option).
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
108
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
HealthStyles Survey
DENOMINATOR
POPULATION
The denominator includes WISEWOMAN participants with high blood pressure or previously
diagnosed with hypertension (high blood pressure)
VALUES AND
DESCRIPTION
1
Yes
Participant reports that she measures her blood pressure at
home or using other calibrated sources
2
No – Was never told
to measure her blood
pressure
Participant reports that she does not measure her blood pressure
at home or using other calibrated sources because she was
never told she should measure her blood pressure
3
No – Doesn’t know
how to measure her
blood pressure
Participant reports that she does not measure her blood pressure
at home or using other calibrated sources because she does not
know how to measure her blood pressure
4
No – Doesn’t have
equipment to measure
her blood pressure
Participant reports that she does not measure her blood pressure
at home or using other calibrated sources because she does not
have access to the required equipment to measure her blood
pressure
5
Not Applicablea
This question is not applicable for the patient because she has
never been diagnosed with hypertension (high blood pressure)
7
Don’t know/Not
sure/Other
Participant is not sure whether she measures her blood pressure
at home or using other calibrated sources or provides some other
reason for why she does not measure her blood pressure at
home (for example, participant chooses not to measure her blood
at home)
This value will be flagged as a quality check
8
Don’t want to answera
Participant did not want to answer whether she measures her
blood pressure at home or using other calibrated sources
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine self-control and management of hypertension (high blood pressure)
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Participants should select one response that is the best option.
Guidance on blood pressure self-monitoring is available in the Self-Measured Blood Pressure
Monitoring Guide by Million Hearts (Centers for Disease Control and Prevention. Self-Measured
Blood Pressure Monitoring: Action Steps for Public Health Practitioners. Atlanta, GA: Centers
for Disease Control and Prevention, US Dept. of Health and Human Services; 2013.)
WISEWOMAN MDE Manual
Edition 18.3
35
Item 6b: BPFreq
FORMAT
How often do you measure your blood pressure at home or using other calibrated
sources?
This variable indicates how frequently the participant measures her blood pressure at home or
using other calibrated sources.
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
109
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
HealthStyles Survey
DENOMINATOR
POPULATION
The denominator includes WISEWOMAN participants with high blood pressure or previously
diagnosed with hypertension (high blood pressure)
VALUES AND
DESCRIPTION
1
Multiple times per day
Participant measures her blood pressure at home or using other
calibrated sources multiple times per day
2
Daily
Participant measures her blood pressure at home or using other
calibrated sources once per day
3
A few times per week
Participant measures her blood pressure at home or using other
calibrated sources a few times per week
4
Weekly
Participant measures her blood pressure at home or using other
calibrated sources once per week
5
Monthly
Participant measures her blood pressure at home or using other
calibrated sources once per month
6
Not Applicablea
This question is not applicable for the patient because she has
never been diagnosed with hypertension (high blood pressure) or
does not monitor her blood pressure at home or using other
calibrated sources
7
Don’t know/Not
sure/Other
Participant is not sure how frequently she measures her blood
pressure at home or using other calibrated sources
This value will be flagged as a quality check
8
Don’t want to answera
Participant did not want to answer how frequently she measures
her blood pressure at home or using other calibrated sources
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine self-control and management of hypertension (high blood pressure)
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
WISEWOMAN MDE Manual
Edition 18.3
36
Item 6c: BPSend
Do you regularly share blood pressure readings with a health care provider for
feedback?
This variable indicates whether the participant shares blood pressure readings taken at home or
using other calibrated sources with a health care provider for feedback almost every time she
sees her provider.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
110
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes WISEWOMAN participants with high blood pressure or previously
diagnosed with hypertension (high blood pressure)
VALUES AND
DESCRIPTION
1
Yes
Participant reports that she shares blood pressure readings taken
at home or using other calibrated sources with a health care
provider for feedback almost every time she sees her provider
2
No
Participant reports that she does not share blood pressure
readings taken at home or using other calibrated sources with a
health care provider for feedback
5
Not Applicablea
This question is not applicable for the patient because she has
never been diagnosed with hypertension (high blood pressure) or
does not monitor her blood pressure at home or using other
calibrated sources
7
Don’t know/Not
sure/Other
Participant is not sure whether she shares blood pressure
readings taken at home or using other calibrated sources with a
health care provider for feedback
This value will be flagged as a quality check
8
Don’t want to answera
Participant did not want to answer whether she shares blood
pressure readings taken at home or using other calibrated
sources with a health care provider for feedback
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine self-control and management of hypertension (high blood pressure)
To determine whether blood pressure monitoring results are shared with a health care provider
for monitoring of progress
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
WISEWOMAN MDE Manual
Edition 18.3
37
Item 7a: FruitVeg*
How many cups of fruits and vegetables do you eat in an average day?
This variable indicates the amount of fruit and vegetables the participant consumes in an
average day.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
2
Justification:
Right
Field Length:
2
Beginning Position:
111
Leading Zeros:
Yes
Valid Range:
01-65; cannot be blank
Static Field:
No
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Number of cups
Two-digit (numeric) value representing the number of cups of fruit
and vegetables the participant consumes in an average day
Any value outside the valid range (01 -65) will be considered an
error
Example: 2 cups = 02
00 None
Participant does not consume fruit or vegetables in an average
day
88 Don’t want to answera
Participant does not want to answer how many cups of fruit and
vegetables she consumes in an average day
This value will be flagged as a quality check
99 No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine the healthy behaviors and CVD risk factors of individual participants and the
overall WISEWOMAN population
To provide data elements required to determine participant’s cardiovascular risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Examples of one cup of fruit and vegetables sourced from the American Heart Association’s
Life’s Simple Seven provided in Appendix F.
Average fruit and vegetable consumption at screening is required for a record to count as a
complete record. If FruitVeg is blank, coded as ‘‘99 No answer recorded,’ or outside of the valid
range (1-65 cups) the record will not count as a complete record.
*Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
38
Item 7b: Fish*
Do you eat fish at least two times a week?
This variable indicates whether the participant consumes two servings or more of fish weekly.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
113
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
Yes
Participant consumes two servings or more of fish weekly
2
No
Participant does not consume two servings or more of fish weekly
8
Don’t want to
answera
Participant does not want to answer whether she consumes two
servings or more of fish weekly
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine the healthy behaviors and CVD risk factors of individual participants and the
overall WISEWOMAN population
To provide data elements required to determine participant’s cardiovascular risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Examples of servings of fish sourced from the American Heart Association’s Life’s Simple
Seven provided in Appendix F.
Average fish consumption at screening is required for a record to count as a complete record. If
Fish is blank or coded as ‘‘9 No answer recorded,’ the record will not count as a complete
record.
*Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
39
Item 7c: Grains*
FORMAT
Thinking about all the servings of grain products you eat in a typical day, how many are
whole grains?
This variable indicates the relative amount of whole grains the participant consumes compared
to the total amount of grains consumed in a typical day.
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
114
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
United States Department of Agriculture
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
Less than half
Less than half of servings of grain products consumed in a typical
day are whole grains
2
About half
About half of servings of grain products consumed in a typical
day are whole grains
3
More than half
More than half of servings of grain products consumed in a
typical day are whole grains
8
Don’t want to answera
Participant does not want to answer how many servings of grain
products consumed in a typical day are whole grains
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine the healthy behaviors and CVD risk factors of individual participants and the
overall WISEWOMAN population To provide data elements required to determine participant’s
cardiovascular risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Examples of servings of whole grains sourced from the American Heart Association’s Life’s
Simple Seven provided in Appendix F.
Average whole grain consumption at screening is required for a record to count as a complete
record. If Grains is blank or coded as ‘‘9 No answer recorded,’ the record will not count as a
complete record.
*Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
40
Item 7d: Sugar*
Do you drink less than 36 ounces (450 calories) of sugar sweetened beverages weekly?
This variable indicates whether the participant drinks less than 36 ounces (450 calories) of
sugar sweetened beverages weekly.
FORMAT
Type:
Numeric
Other Format:
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
115
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
N/A
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
Yes
Participant consumes less than 36 ounces (450 calories) of
beverages with added sugars in an average week
2
No
Participant consumes 36 ounces or more (450 calories or more)
of beverages with added sugars in an average week
8
Don’t want to answera
Participant does not want to answer whether she consumes less
than 36 ounces (450 calories) or more of beverages with added
sugars in an average week
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine the healthy behaviors and CVD risk factors of individual participants and the
overall WISEWOMAN population
To provide data elements required to determine participant’s cardiovascular risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Examples of 36 ounces of beverages with added sugars sourced from the American Heart
Association’s Life’s Simple Seven provided in Appendix F.
Average sugar-sweetened beverage consumption at screening is required for a record to count
as a complete record. If Sugar is blank or coded as ‘‘9 No answer recorded,’ the record will not
count as a complete record.
*Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
41
Item 7e: SaltWatch*
Are you currently watching or reducing your sodium or salt intake?
This variable indicates whether the participant is currently watching or reducing her sodium or
salt intake.
FORMAT
Type:
Numeric
Other Format:
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
116
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
N/A
SOURCE
CDC Behavioral Risk Factor Surveillance System
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
Yes
Participant is currently watching or reducing her sodium or salt
intake
2
No
Participant is not currently watching or reducing her sodium or
salt intake
8
Don’t want to answera
Participant does not want to answer whether she is currently
watching or reducing her sodium or salt intake
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine the healthy behaviors and CVD risk factors of individual participants and the
overall WISEWOMAN population
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Whether a participant is watching her sodium intake at screening is required for a record to
count as a complete record. If Saltwatch is blank or coded as ‘‘9 No answer recorded,’ the
record will not count as a complete record.
*Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
42
Item 7f: AlcFreq
In the past 7 days, how often do you have a drink containing alcohol?
This variable indicates the number of days during the past 7 days that a participant had a drink
containing alcohol.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
2
Justification:
Right
Field Length:
2
Beginning Position:
117
Leading Zeros:
Yes
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
Alcohol Use Disorders Identification Test
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Number of days
A two-digit (numeric) value representing the number of days
during the past 7 days that the participant consumed a drink that
contained alcohol. Any value outside the valid range (00-07) will
be considered a quality check.
Example: 4 days = 04
00 None
Participant has not consumed any drinks containing alcohol
during the past 7 days
88 Don’t want to answera
Participant does not want to answer how many days during the
past 7 days she has consumed drinks containing alcohol
This value will be flagged as a quality check
99 No answer recordeda
No answer recorded
This value will be flagged as a quality check
ANALYSIS AND USE
To determine the healthy behaviors and CVD risk factors of individual participants and the
overall WISEWOMAN population
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
WISEWOMAN MDE Manual
Edition 18.3
43
Item 7g: AlcDay
How many alcoholic drinks, on average, do you consume during a day you drink?
This variable indicates the average number of alcoholic drinks consumed during a day.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
2
Justification:
Right
Field Length:
2
Beginning Position:
119
Leading Zeros:
Yes
Valid Range:
Static Field:
No
See values; cannot
be blank
SOURCE
Alcohol Use Disorders Identification Test
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Number of drinks
A numeric value indicating the average number of alcoholic
drinks consumed during a day when the participant is
drinking alcohol
Any value outside the valid range (00 – 50) will be
considered a quality check.
00 None
The participant does not consume any alcoholic drinks
88 Don’t want to answera
Participant did not want to answer the average number of
alcoholic drinks she consumes during a day when she is
drinking alcohol
This value will be flagged as a quality check
99 No answer recordeda
No answer recorded
This value will be flagged as a quality check
ANALYSIS AND USE
To determine the healthy and risky behaviors and CVD risk factors of individual participants and
the overall WISEWOMAN population
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
A standard alcoholic drink is defined in Appendix F and as the follows: 12 fluid ounces of beer
(about 5% alcohol), 8-9 fluid ounces of malt liquor (about 7% alcohol), 5 fluid ounces of wine
(about 12% alcohol), or a 1.5 fluid ounce shot of 80 proof spirits (e.g., vodka, rum, gin, whiskey,
tequila; about 40% alcohol).
WISEWOMAN MDE Manual
Edition 18.3
44
Item 8a: PA*
How many minutes of physical activity (exercise) do you get in a week?
This variable indicates the amount of physical activity the participant gets during an average
week.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
4
Justification:
Right
Field Length:
4
Beginning Position:
121
Leading Zeros:
Yes
Valid Range:
Static Field:
No
010-1700; cannot be
blank
SOURCE
American Heart Association Life’s
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Number of minutes
A four-digit (numeric) value representing the minutes of physical
activity the participant gets during an average week
Any value outside the valid range (0010 – 1700) will be considered a
quality check
Example: 30 minutes = 0030
If the number of minutes of physical activity exceeds 1700 minutes,
PA should be coded as 1700 and the number of minutes of physical
activity should be documented using the Validation of Data form. See
Appendix B for the procedure for validating out-of-range values.
0000 None
Participant does not get any physical activity during an average week
8888 Don’t want to
answera
Participant does not want to answer how much physical activity she
gets during an average week
This value will be flagged as a quality check
9999 No answer
recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND USE
To determine the healthy behaviors and CVD risk factors of individual participants and the
overall WISEWOMAN population
To provide data elements required to determine participant’s cardiovascular risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Examples of physical activity sourced from the American Heart Association’s Life’s Simple
Seven provided in Appendix F.
Average physical activity at screening is required for a record to count as a complete record. If
PA is blank or coded as ‘‘9999 No answer recorded,’ the record will not count as a complete
record.
*Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
45
Item 9a: Smoker*
Do you smoke? Includes cigarettes, pipes, or cigars (smoked tobacco in any form)
This variable indicates whether the participant smokes tobacco in any form, including cigarettes,
pipes, or cigars.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
125
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening
VALUES AND
DESCRIPTION
1
Current Smoker
Participant currently smokes tobacco in any form, including
cigarettes, pipes, or cigars
2
Quit (1-12 months ago)
Participant quit smoking tobacco in any form, including cigarettes,
pipes, or cigars, 1 to 12 months ago
3
Quit (More than 12
months ago)
Participant quit smoking tobacco in any form, including cigarettes,
pipes, or cigars, more than 12 months ago
4
Never Smoked
Participant has never smoked tobacco in any form, including
cigarettes, pipes, or cigars
8
Don’t want to answera
Participant does not want to answer whether she smokes tobacco
in any form, including cigarettes, pipes, or cigars
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND
USE
To determine the healthy behaviors and CVD risk factors of individual participants and the overall
WISEWOMAN population
To identify participants who might benefit from smoking cessation counseling and tobacco
cessation resources (quit line and community-based)
To provide data elements required to determine participant’s ASCVD risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Smoking status at screening is required for a record to count as a complete or BP+ record. If
Smoker is blank or coded as ‘‘9 No answer recorded,’ the record will not count as a complete or
BP+ record, which means the record will not count toward meeting a program’s screening goal.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
46
Item 10a: PHQ*
Over the past 2 weeks, how often have you been bothered by any of the following
problems?
i.
Little interest or pleasure in doing things (not at all, several days, more than half,
or nearly every day)?
ii.
Feeling down, depressed, or hopeless (not at all, several days, more than half, or
nearly every day)?
This variable indicates the number of days during the past two weeks that the participant felt little
interest or pleasure in doing things and felt down, depressed, or hopeless.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
2
Justification:
Right
Field Length:
2
Beginning Position:
126
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank
SOURCE
Patient Health Questionnaire (PHQ-2)
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening
VALUES AND
DESCRIPTION
(CODE FOR EACH
ISSUE)
0
Not at all
Participant has not been bothered by this issue at all over the past
two weeks
1
Several days
Participant has been bothered by this issue several days over the
past two weeks
2
More than half
Participant has been bothered by this issue more than half the
days over the past two weeks
3
Nearly every day
Participant has been bothered by this issue nearly every day over
the past two weeks
8
Don’t want to answera
Participant does not want to answer how often she has been
bothered by this issue
This value will be flagged as a quality check
9
No answer recordeda
No answer recorded
This value will be flagged as an error
ANALYSIS AND
USE
To determine the health status of individual participants and the overall WISEWOMAN population
To provide health status information for cost benefit or cost effectiveness analyses
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
presented to participants. They are provided for funded program use only.
Each of the two positions in the PHQ field corresponds with a different question. The first position
aligns how often the participant reports having little interest in doing things. The second position
aligns with how often the participant reports feeling down, depressed, or hopeless.
Programs should assess each question separately and record the corresponding value in the
appropriate position of 10a: PHQ. For example, if a participant reports that she: (a) has felt little
interest in doing things “several days” in the past two weeks and (b) has felt down, depressed, or
hopeless “more than half the days” in the past two weeks, PHQ should be recorded as ‘12’
(corresponding to values of ‘1 – Several days’ in position 1 and ‘2 – More than half’ in position 2).
*Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
47
Item 11a: Height*
Height
This variable indicates the participant’s height in inches at baseline screening.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
2
Justification:
Right
Field Length:
2
Beginning Position:
128
Leading
Zeros:
No
Valid Range:
Static Field:
Yes
48-76; cannot be blank if TYPE is
1, 2, 3 or 4 (baseline screening,
rescreening, or follow-up)
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Height in inches
Up to a two-digit (numeric) value representing the participant’s
height at baseline screening
Height values between 48" and 58" or 74" and 76" will be flagged
for quality checks and program verification. See Appendix B for
the procedure for validating out-of-range values. Any values
outside 48"-76" will be considered an error
Example: 62" (5 feet, 2 inches) = 62
77 Unable to obtain
Height measurement was attempted, but measurement results
were not obtained. See Appendix B for the procedure for
documenting the reason that the measurement was not obtained
This value will be flagged as an error
88 Client refuseda
Participant refuses to have her height measurement taken
This value will be flagged as an error
99 No measurement
recordeda
Height measurement was not performed
This value will be flagged as an error
ANALYSIS AND USE
To calculate the BMI of WISEWOMAN participants
To understand the cardiovascular disease risk factors of individual participants and the overall
WISEWOMAN population
To provide data elements required to determine participant’s cardiovascular risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
All height measurements should be recorded in inches.
Height measurement at screening is required for a record to count as a complete or BP+ record.
If Height is blank or coded as ‘777 Unable to obtain,’ ‘888 Client refused,’ or ‘999 No
measurement recorded,’ or is outside of the valid range (48-76 inches) the record will not count
as a complete or BP+ record, and the record will not count toward meeting a program’s
screening goal. If exceptional circumstances do not allow height measurement, these reasons
should be documented in the Validation of Data form as instructed in Appendix B.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
48
Item 11b: Weight*
Weight
This variable indicates the participant’s weight in pounds.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
3
Justification:
Right
Field Length:
3
Beginning Position:
130
Leading
Zeros:
Yes
Valid Range:
Static Field:
No
074-460; cannot be blank if TYPE
is 1, 2, 3 or 4 (baseline screening,
rescreening, or follow-up)
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Weight in pounds
Up to a three-digit (numeric) value representing the participant’s
weight
Weight values between 74 and 90 lbs. or 350 and 460 lbs. will be
flagged for quality checks and program verification. See Appendix B
for the procedure for validating out-of-range values. Any values
outside 74-460 lbs. will be considered an error
Example: 98 lbs. = 098
777 Unable to obtain
Weight measurement was attempted, but measurement results were
not obtained
This value will be flagged as a quality check. See Appendix B for the
procedure for documenting the reason that the measurement was
not obtained
888 Client refuseda
Participant refuses to have her weight measurement taken
This value will be flagged as a quality check
999 No measurement
recordeda
Weight measurement was not performed
This value will be flagged as an error
ANALYSIS AND USE
To calculate the BMI of WISEWOMAN participants
To understand the cardiovascular disease risk factors of individual participants and the overall
WISEWOMAN population
To provide data element required to determine participant’s cardiovascular risk
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection
forms completed by the provider. They are provided for funded program use only.
Weight measurement at screening is required for a record to count as a complete or BP+
record. If Weight is blank or coded as ‘999 No measurement recorded,’ or is outside of the
valid range (74-460 lbs.) the record will not count as a complete or BP+ record, and the
record will not count toward meeting a program’s screening goal. If exceptional
circumstances do not allow weight measurement, these reasons should be documented in
the Validation of Data form, as instructed in Appendix B.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
49
Item 11c: Waist
Waist Circumference
This variable indicates the participant’s waist circumference in inches.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
2
Justification:
Right
Field Length:
2
Beginning Position:
133
Leading Zeros:
No
Valid Range:
16-71
Static Field:
No
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Waist Circumference in
inches
Up to a two-digit (numeric) value representing the participant’s
waist circumference in inches
Any value outside the valid range (16 – 71 inches) will be flagged
as a quality check
Example: 30 inches = 30
77 Unable to obtain
Waist circumference measurement was attempted, but
measurement results were not obtained
88 Client refuseda
Participant refuses to have her waist circumference measurement
taken
99 No measurement
recordeda
Waist circumference measurement was not performed
ANALYSIS AND USE
To understand the cardiovascular disease risk factors of individual participants and the overall
WISEWOMAN population
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
WISEWOMAN MDE Manual
Edition 18.3
50
Item 12a: BPDate*
Clinical Assessment Date (Office Visit Date)
This variable indicates the date of the office visit for a participant.
FORMAT
Type:
Numeric
Other Format:
MMDDCCYY
Item Length:
8
Justification:
Right
Field Length:
8
Beginning Position:
135
Leading Zeros:
Yes
Valid Range:
Valid date
Static Field:
No
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Clinical assessment
date/Office visit date
ANALYSIS AND USE
To identify the date of the screening office visit
To facilitate analysis of changes in blood pressure over time
To calculate other service time frames, including time to rescreening, lifestyle program
sessions, lifestyle program/health coaching follow-up screening, risk reduction counseling
sessions, alert referrals, and labs
Valid date in MMDDCCYY format
Date of the office visit for a participant
Example: September 10, 2018 = 09102018
OTHER
INFORMATION
Clinical assessment date should be used to indicate the date that the screening visit occurred.
If BPDate is missing or invalid, the record will not count as a complete or BP+ record, and the
record will not count toward meeting a program’s screening goal.
Since all screening measurements and assessments are to be used to determine participation
in the lifestyle programs and health coaching, it is expected that all labs and other screening
services will be completed within as short a time frame as possible. Thirty days is the
recommended time frame in which blood pressure measurements should be done prior to or
after the clinical assessment date unless specified by the program’s medical advisory group or
medical clinic.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
51
Item 12b: SBP*
Systolic Blood Pressure
This variable indicates the participant’s systolic blood pressure readings.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
3
Justification:
Right
Field Length:
12
Beginning Position:
143
Leading Zeros:
Yes
Valid Range:
Static Field:
No
074-260; cannot be blank if TYPE
is 1, 2, 3 or 4 (baseline screening,
rescreening or follow-up)
SOURCE
Not applicable; health screening measurement
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
(CODE FOR EACH
READING AND IN
THE ORDER TAKEN)
Systolic blood pressure
in mmHg
A three-digit (numeric) value representing the participant’s
systolic blood pressure in mmHg
Systolic blood pressure values between 230 and 260 mmHg will
be flagged for quality checks and program verification. Values
outside 74-260 mmHg will be flagged as errors. See Appendix B
for the procedure for validating out-of-range values
If a blood pressure measurement was not obtained at the time of
the office visit and obtained at a referral visit within 30 days of the
visit, the blood pressure measurement from the referral should be
recorded here
Example: 90 mmHg = 090
777 Unable to obtain
Systolic blood pressure measurement was attempted, but results
were not obtained due to technical difficulties or errors
See Appendix B for the procedure for documenting the reason
that the measurement could not be obtained
This value will be flagged as an error
888 Client refuseda
Participant refuses to have her systolic blood pressure
measurement taken
This value will be flagged as an error
999 No measurement
recordeda
Systolic blood pressure measurement was not performed or not
recorded
This value will be flagged as an error
ANALYSIS AND USE
To identify those at increased risk for cardiovascular conditions, including heart attack, heart
failure, stroke, and kidney disease
To identify participants who would benefit from lifestyle programs
To identify participants unaware that they have hypertension (high blood pressure) for referral to
medical management
To determine control and management of blood pressure
To identify participants who require further diagnostic evaluation
To identify hypertension (high blood pressure) risk of the WISEWOMAN population
To provide data element required to determine participant’s cardiovascular risk score
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
Programs can submit up to four systolic blood pressure measurements. The first measurement
(positions 1 through 3 of SBP) should correspond to the systolic blood pressure measurement
on the clinical assessment date. If more than one measurement is obtained on the clinical
assessment date, with a one minute interval as recommended by the American Heart
Association, the average systolic blood pressure measurement should be recorded in positions
1 through 3.
WISEWOMAN MDE Manual
Edition 18.3
52
OTHER
INFORMATION
(CONT.)
Programs may re-measure participants’ systolic blood pressure prior to a subsequent follow-up
screening or rescreening. If a program re-measures a participant’s systolic blood pressure
during follow-up, up to three additional systolic blood pressure measurements can be recorded
in positions 4 through 6 (re-measurement #1), positions 7 through 9 (re-measurement #2), and
positions 10 through 12 (re-measurement #3). Programs are not required to submit blood
pressure re-measurements (positions 4 through 12); however, if blood pressure remeasurements are recorded, the date of re-measurement should be provided in 5d: Monitored.
Systolic blood pressure measurement at screening (positions 1 through 3 of SBP) is required for
a record to count as a complete or BP+ record. If positions 1 through 3 of SBP are blank or
coded as ‘777 Unable to obtain,’ ‘888 Client refused,’ or ‘999 No measurement recorded,’ or is
outside of the valid range (74-260 mmHg) the record will not count as a complete or BP+
record, and the record will not count toward meeting a program’s screening goal. If exceptional
circumstances do not allow a blood pressure measurement during the clinical assessment
(cases where positions 1 through 3 of SBP are coded as ‘777 Unable to obtain’), these reasons
should be documented as instructed in Appendix B.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
53
Item 12c: DBP*
Diastolic Blood Pressure
This variable indicates the participant’s diastolic blood pressure readings.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
3
Justification:
Right
Field Length:
12
Beginning Position:
155
Leading Zeros:
Yes
Valid Range:
Static Field:
No
002-156; cannot be blank if TYPE
is 1, 2, 3 or 4 (baseline screening,
rescreening or follow-up)
SOURCE
Not applicable; health screening measurement
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
(CODE FOR EACH
READING AND IN
THE ORDER TAKEN)
Diastolic blood pressure
in mmHg
A three-digit (numeric) value representing the participant’s
diastolic blood pressure in mmHg
Diastolic blood pressure values between 2-12 mmHg or 122-156
mmHg will be flagged for quality checks and program verification.
Values outside 2-156 mmHg will be considered errors. See
Appendix B for the procedure for validating out-of-range values
If a blood pressure measurement was not obtained at the time of
the office visit and obtained at a referral visit within 30 days of the
visit, the blood pressure measurement from the referral should be
recorded here
Example: 85 mmHg = 085
777 Unable to obtain
Diastolic blood pressure measurement was attempted, but results
were not obtained due to technical difficulties or errors
See Appendix B for the procedure for documenting the reason that
the measurement could not be obtained
This value will be flagged as an error
888 Client refuseda
Participant refuses to have her diastolic blood pressure
measurement taken
This value will be flagged as an error
999 No measurement
recordeda
Diastolic blood pressure measurement was not performed or not
recorded
This value will be flagged as an error
ANALYSIS AND USE
To identify those at increased risk for cardiovascular conditions, including heart attack, heart
failure, stroke, and kidney disease
To identify participants who would benefit from lifestyle programs
To identify participants unaware that they have hypertension(high blood pressure) for referral to
medical management
To determine control and management of blood pressure
To identify participants who require further diagnostic evaluation
To identify hypertension (high blood pressure) risk of the WISEWOMAN population
To provide data element required to determine participant’s cardiovascular risk score
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
Programs can submit up to four diastolic blood pressure measurements. The first measurement
(positions 1 through 3 of DBP) should correspond to the diastolic blood pressure measurement
on the clinical assessment date. If more than one measurement is obtained on the clinical
assessment date, with a one minute interval as recommended by the American Heart
Association, the average diastolic blood pressure measurement should be recorded in positions
1 through 3.
WISEWOMAN MDE Manual
Edition 18.3
54
OTHER
INFORMATION
(CONT.)
Programs may re-measure participants’ diastolic blood pressure prior to a subsequent follow-up
screening or rescreening. If a program re-measures a participant’s diastolic blood pressure
during follow-up, up to three additional diastolic blood pressure measurements can be recorded
in positions 4 through 6 (re-measurement #1), positions 7 through 9 (re-measurement #2), and
positions 10 through 12 (remeasurement #3). Programs are not required to submit blood
pressure re-measurements (positions 4 through 12); however, if blood pressure remeasurements are recorded, the date of re-measurement should be provided in 5d: Monitored.
Diastolic blood pressure measurement at screening (positions 1 through 3 of DBP) is required
for a record to count as a complete or BP+ record. If positions 1 through 3 of DBP is blank or
coded as ‘777 Unable to obtain,’ ‘888 Client refused,’ or ‘999 No measurement recorded,’ or is
outside of the valid range (2-156 mmHg) the record will not count as a complete or BP+ record,
and the record will not count toward meeting a program’s screening goal. If exceptional
circumstances do not allow a blood pressure measurement (cases where first blood pressure
measurement is coded as ‘777 Unable to obtain’), these reasons should be documented as
instructed in Appendix B.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
55
Item 13a: Fast*
Fasting Status
This variable indicates whether a participant fasted for at least nine hours prior to having
blood drawn for cholesterol or glucose measurements.
FORMAT
Type:
Numeric
Other Format:
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
167
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be blank if
TYPE is 1 or 2 (baseline
screening or rescreening);
cannot be blank if Type = 3 or
4 when any of the following
are not blank: Totchol, HDL,
LDL, Trigly, glucose
N/A
SOURCE
Not applicable; health screening measurement
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
1
Yes
Participant fasted for at least nine hours prior to having blood
drawn
2
No
Participant did not fast for at least nine hours prior to having
blood drawn
9
No answer
recordeda
No answer recorded
Provider failed to confirm fasting status or no information is
available from the provider
This value should be marked if 14a: TotChol, 14b: HDL, 14c:
LDL, 14d: Trigly, and 15a: Glucose all are equal to 999/9999,
777/7777, or 888/8888
This value will be flagged as an error for baseline screenings,
and rescreenings, and for follow-up screenings where labwork
was conducted
ANALYSIS AND USE
To facilitate accurate identification of participants who have high cholesterol, borderline high
cholesterol, diabetes, or pre-diabetes
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection
forms completed by the provider. They are provided for funded program use only.
If a participant reports that she doesn’t know or refuses blood work, programs should have a
discussion with the participant to verify the response.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
56
Item 14a: TotChol*
Total Cholesterol (fasting or nonfasting)
This variable indicates the participant’s total cholesterol level.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
3
Justification:
Right
Field Length:
3
Beginning Position:
168
Leading Zeros:
Yes
Valid Range:
Static Field:
No
044-702; cannot be blank if
TYPE is 1 or 2 (baseline
screening or rescreening)
SOURCE
Not applicable; health screening measurement
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Total cholesterol in
mg/dL
A three-digit (numeric) value representing the participant’s total
cholesterol in mg/dL
Total cholesterol values that are between 44 and 60 mg/dL or 400
and 702 mg/dL will be flagged for quality checks and program
verification. Values outside 44-702 will be considered errors. See
Appendix B for the procedure for validating out-of-range values
Example: 90 mg/dL = 090
777 Inadequate blood
sample
Total cholesterol measurement was attempted, but results were not
obtained due to technical difficulties or errors
This may include issues such as (1) two or more failed venipuncture
attempts; (2) insufficient amount of blood, type of test tube; (3)
invalid Cholestech readings due to very high/low values; (4) sample
submitted to laboratory, test not done due to erroneous or missing
laboratory request or other paperwork
See Appendix B for the procedure for documenting the reason that
the measurement was not obtained
This value will be flagged as an error
888 Client refuseda
Participant refuses to have her blood drawn for cholesterol
measurements
If the participant refuses to go to the lab, the participant can be
considered to have refused
If the participant does not go to the scheduled lab appointment after
follow-up has been attempted, the participant can be considered to
have refused
This value will be flagged as an error
999 No measurement
recordeda
No total cholesterol measurement was taken or recorded
This value will be flagged as an error for baseline screenings and
rescreenings
ANALYSIS AND USE
To identify participants who are unaware that they have high or borderline high cholesterol and
need preventive services or referral to medical management
To determine cholesterol control and management
To assess the percentage of WISEWOMAN participants who have high cholesterol or
borderline high cholesterol
To assess the risk in the WISEWOMAN population for cardiovascular disease
To provide data element required to determine participant’s cardiovascular risk score
WISEWOMAN MDE Manual
Edition 18.3
57
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
Total cholesterol measurement may be taken as fasting or nonfasting. At a minimum, every
participant must have a total cholesterol,HDL cholesterol (14b: HDL), and LDL cholesterol (14c:
LDL) value recorded.
Total cholesterol measurement at baseline screening or rescreening is required for a record to
count as a complete or BP+ record. If TotChol is blank or coded as ‘777 Unable to obtain,’ ‘888
Client refused, or ‘999 No measurement recorded,’ or is outside of the valid range (044-702
mg/dL) the record will not count as a complete or BP+ record. If exceptional circumstances do
not allow TotChol measurement, these reasons should be documented in the Validation of Data
form as instructed in Appendix B.
Total cholesterol measurement may not be medically necessary at follow-up screening if a
participant had normal cholesterol levels at baseline screening anchored in American Heart
Association guidelines.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
58
Item 14b: HDL*
HDL Cholesterol (fasting or nonfasting)
This variable indicates the participant’s HDL cholesterol level.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
3
Justification:
Right
Field Length:
3
Beginning Position:
171
Leading Zeros:
Yes
Valid Range:
Static Field:
No
007-196; cannot be blank if
TYPE is 1 or 2 (baseline
screening or rescreening)
SOURCE
Not applicable; health screening measurement
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
HDL cholesterol in
mg/dL
A three-digit (numeric) value representing the participant’s HDL
cholesterol in mg/dL
HDL cholesterol values that are between 155 and 196 mg/dL will be
flagged for quality checks and program verification. Values outside
007-196 mg/dL will be considered errors. See Appendix B for the
procedure for validating out-of-range values
Example: 90 mg/dL = 090
777 Inadequate blood
sample
HDL cholesterol measurement was attempted, but results were not
obtained due to technical difficulties or errors
This may include issues such as (1) two or more failed venipuncture
attempts; (2) insufficient amount of blood, type of test tube; (3)
invalid Cholestech readings due to very high/low values;(4) sample
submitted to laboratory, test not done due to erroneous or missing
laboratory request or other paperwork
See Appendix B for the procedure for documenting the reason that
the measurement was not obtained
This value will be flagged as an error
888 Client refuseda
Participant refuses to have her blood drawn for cholesterol
measurements
If the participant refuses to go to the lab, the participant can be
considered to have refused
If the participant does not go to the scheduled lab appointment after
follow-up has been attempted, the participant can be considered to
have refused
This value will be flagged as an error
999 No measurement
recordeda
No HDL cholesterol measurement was taken or recorded
This value will be flagged as an error for baseline screenings and
rescreenings
ANALYSIS AND USE
To identify participants who are unaware that they have low HDL cholesterol and need
preventive services or referral to medical management
To assess the percentage of WISEWOMAN participants who have high cholesterol or
borderline high cholesterol
To assess the risk of the WISEWOMAN population for cardiovascular disease
To assist in determining cholesterol control and management
WISEWOMAN MDE Manual
Edition 18.3
59
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
HDL cholesterol measurement may be taken as fasting or nonfasting. At a minimum, every
participant must have a total cholesterol,HDL cholesterol (14b: HDL), and LDL cholesterol (14c:
LDL) value recorded.
In cases where the Cholestech machine indicates a reading of less than 15 mg/dL, the
guidance is to code the participant’s HDL as 015.
HDL cholesterol measurement at baseline screening or rescreening is required for a record to
count as a complete or BP+ record. If HDL is blank or coded as ‘777 Unable to obtain,’ ‘888
Client refused, or ‘999 No measurement recorded,’ or is outside of the valid range (007-196
mg/dL) the record will not count as a complete or BP+ record. If exceptional circumstances do
not allow HDL measurement, these reasons should be documented in the Validation of Data
form as instructed in Appendix B.
HDL cholesterol measurement may not be medically necessary at follow-up screening if a
participant had normal cholesterol levels at baseline screening anchored in American Heart
Association guidelines.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
60
Item 14c: LDL*
LDL Cholesterol (fasting or nonfasting)
This variable indicates a participant’s LDL cholesterol level
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
3
Justification:
Right
Field Length:
3
Beginning Position:
174
Leading Zeros:
Yes
Valid Range:
Static Field:
No
020-380: cannot be blank if
TYPE is 1 or 2 (baseline
screening or rescreening)
SOURCE
2018 AHA/ACC Guideline on the Management of Blood Cholesterol
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
LDL cholesterol in
mg/dL
A three-digit (numeric) value representing a participant’s LDL
cholesterol in mg/dL
LDL cholesterol values that are between 344 and 380 mg/dL will be
flagged for quality checks and program verification. LDL cholesterol
values that are outside 020 and 380 mg/dL will be considered errors.
See Appendix B for the procedure for validating out-of-range values
For nonfasting participants who are on lipid-lowering therapy, have a
history of high cholesterol, or have a triglyceride level >0400 mg/dL,
any value in this field will be flagged for an error. See below for
additional guidance
Example: 90 mg/dL = 090
777 Inadequate blood
sample
LDL cholesterol measurement was attempted, but results were not
obtained due to technical difficulties or errors
This may include issues such as (1) two or more failed venipuncture
attempts; (2) insufficient amount of blood, type of test tube; (3)
invalid Cholestech readings due to very high/low values; (4) sample
submitted to laboratory, test not done due to erroneous or missing
laboratory request or other paperwork
This response should also be used for participants on lipid-lowering
therapy with a history of high cholesterol who were confirmed to be
fasting, but their LDL cholesterol was unable to be obtained.
This value will be flagged as an error.
888 Client refuseda
Participant refuses to receive a lipid panel that would include LDL
measurements
This response should also be used for participants on lipid-lowering
therapy or with a history of high cholesterol who were confirmed to
be fasting, but refused a lipid panel
This value will be flagged as an error.
999 No measurement
recordeda
No LDL cholesterol measurement was taken or recorded
Nonfasting participants who are on lipid-lowering therapy, have a
history of high cholesterol, or have a triglyceride level >0400 mg/dL
should always have this value
ANALYSIS AND USE
To assist in determining cholesterol control and management
WISEWOMAN MDE Manual
Edition 18.3
61
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
At a minimum, every participant must have a total cholesterol, HDL cholesterol (14b: HDL) and
LDL cholesterol (14C: LDL) value recorded.
LDL cholesterol measurement at baseline screening or rescreening is required for a record to
count as a complete or BP+ record. If LDL is blank or coded as ‘777 Unable to obtain,’ ‘888
Client refused, or ‘999 No measurement recorded,’ or is outside of the valid range (020-380
mg/dL) the record will not count as a complete or BP+ record. If exceptional circumstances do
not allow LDL measurement, these reasons should be documented in the Validation of Data
form as instructed in Appendix B.
LDL cholesterol measurement may not be medically necessary at follow-up screening if a
participant had normal cholesterol levels at baseline screening based on American Heart
Association guidelines.
As per the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol, measurement
of either a fasting or a nonfasting plasma lipid profile is effective in estimating initial ASCVD risk
if the participant is not on lipid-lowering therapy and does not have a history of high cholesterol.
Therefore, although assessing lipids when the participant is fasting may be more prudent, for
participants not on lipid-lowering therapy and without a history of high cholesterol, LDL
cholesterol may be measured for fasting or nonfasting participants. It is not recommended to
measure nonfasting LDL if a participant has consumed an extremely high-fat meal 8 hours prior
to blood work. In this case, blood work should be measured on another day (preferably fasting).
Additionally, for any participants with a family history of heart attacks or other atherosclerotic
disease at an early age (< 50-55 years) or who have a genetic history of hyperlipidemia, it is
reasonable to obtain an initial fasting lipid profile.
For participants on lipid-lowering therapy, or who have a history of high cholesterol, LDL
cholesterol should be measured only when the participant is fasting. If a participant meets either
of these criteria and is not fasting when cholesterol is initially measured, the provider may remeasure fasting cholesterol within 30 days of the office visit. In this case, the fasting status
(13a: Fast), total cholesterol (14a:TotChol), HDL cholesterol (14b:HDL), LDL cholesterol (14c:
LDL), and triglycerides (14d:trigly) values should also be updated in the screening record.
For participants who are not on lipid-lowering therapy and do not have a history of high
cholesterol, but who were not fasting and had a triglyceride (14d: Trigly) level greater than or
equal to 400 mg/dL, blood work should be performed again as a fasting measurement within 30
days of the initial screening. In this case, the fasting status (13a: Fast), total cholesterol
(14a:TotChol), HDL cholesterol (14b:HDL), LDL cholesterol (14c: LDL), and triglycerides
(14d:Trigly) values should also be updated in the screening record.
If an LDL measurement is recorded when the participant was not confirmed to be fasting,
programs should check with providers to determine whether the participant actually was fasting.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
62
Item 14d: Trigly
Triglycerides (fasting or nonfasting)
This variable indicates a participant’s triglycerides measurement.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
4
Justification:
Right
Field Length:
4
Beginning Position:
177
Leading Zeros:
Yes
Valid Range:
0012-3000
Static Field:
No
SOURCE
2018 AHA/ACC Guideline on the Management of Blood Cholesterol
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Triglycerides in mg/dL
A four-digit (numeric) value representing a participant’s triglycerides
measurement in mg/dL
For fasting participants, triglycerides values between 1,000 and
3,000 mg/dL will be flagged for quality checks and program
verification. Values outside 0012-3000 mg/dL will be considered
errors. See Appendix B for the procedure for validating out-of-range
values
For nonfasting participants who are on lipid-lowering therapy or have
a history of high cholesterol, any value in this field will be flagged for
an error
For nonfasting participants who are NOT on a lipid-lowering therapy
and do NOT have a history of high cholesterol, a triglycerides level
outside 0012-0400 mg/dL will be flagged for an error. In this case,
programs should repeat the lipid panel within 30 days to obtain the
fasting values. See additional guidance below
Example: 90 mg/dL = 0090
ANALYSIS AND USE
7777 Inadequate
blood sample
Triglycerides measurement was attempted, but results were not
obtained due to technical difficulties or errors
This may include issues such as (1) two or more failed venipuncture
attempts; (2) insufficient amount of blood, type of test tube; (3)
invalid Cholestech readings due to very high/low values; (4) sample
submitted to laboratory, test not done due to erroneous or missing
laboratory request or other paperwork
This response should also be used for participants on lipid-lowering
therapy or with a history of high cholesterol who were confirmed to
be fasting, but their triglycerides measurement could not be obtained
8888 Client refuseda
Fasting participant refuses to receive a lipid panel that would include
triglycerides measurements
This response should also be used for participants on lipid-lowering
therapy or with a history of high cholesterol who were confirmed to
be fasting, but refused a lipid panel
9999 No measurement
recordeda
No triglycerides measurement was taken or recorded
Nonfasting participants who are on lipid-lowering therapy or have a
history of high cholesterol should always have this value
To assist in determining cholesterol control and management
WISEWOMAN MDE Manual
Edition 18.3
63
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
At a minimum, every participant must have a total cholesterol, HDL cholesterol (14b: HDL) and
LDL cholesterol (14C: LDL). A triglyceride (14d: Trigly) value can also be recorded in addition to
total cholesterol, HDL cholesterol, and LDL cholesterol. Triglycerides measurement may not be
medically necessary at follow-up screening if a participant had normal cholesterol levels at
baseline screening based on American Heart Association guidelines
As per the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol, measurement
of either a fasting or a nonfasting plasma lipid profile is effective in estimating initial ASCVD risk
if the participant is not on lipid-lowering therapy and does not have a history of high cholesterol.
Therefore, although assessing lipids when the participant is fasting may be more prudent, for
participants not on lipid-lowering therapy and without a history of high cholesterol, triglycerides
may be measured for fasting or nonfasting participants. It is not recommended to measure
nonfasting triglycerides if a participant has consumed an extremely high-fat meal 8 hours prior
to blood work. In this case, blood work should be measured on another day (preferably fasting).
Additionally, for any participants with a family history of heart attacks or other atherosclerotic
disease at an early age (< 50-55 years) or who have a genetic history of hyperlipidemia, it is
reasonable to obtain an initial fasting lipid profile.
For participants on lipid-lowering therapy or with a history of high cholesterol, triglycerides
should be measured only when the participant is fasting. If a participant is not fasting when
cholesterol is initially measured, the provider may re-measure fasting cholesterol within 30 days
of the office visit. In this case, the fasting status (13a: Fast), total cholesterol (14a:TotChol),
HDL cholesterol (14b: HDL), LDL cholesterol (14c: LDL), and triglycerides (14d: Trigly) values
should also be updated in the screening record.
For participants who are not on lipid-lowering therapy and do not have a history of high
cholesterol, but who were not fasting and had a triglyceride level greater than or equal to 400
mg/dL, blood work should be performed again as a fasting measurement within 30 days of the
initial screening. If a provider decides to re-measure the cholesterol within 30 days of the office
visit so that the values are fasting, the fasting status (13a:Fast), total cholesterol (14a:TotChol),
HDL cholesterol (14b:HDL), LDL cholesterol (14c: LDL), and triglycerides (14d:Trigly) values
should also be updated in the screening record.
If a triglyceride measurement is recorded when the participant was not confirmed to be fasting,
programs should check with providers to determine whether the participant actually was fasting.
WISEWOMAN MDE Manual
Edition 18.3
64
Item 15a: Glucose*
Glucose (fasting)
This variable indicates the participant’s fasting glucose measurement.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
3
Justification:
Right
Field Length:
3
Beginning Position:
181
Leading Zeros:
Yes
Valid Range:
Static Field:
No
037-571; cannot be blank if A1C is
invalid and TYPE is 1 or 2
(baseline screening or
rescreening)
SOURCE
American Heart Association
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Total glucose in
mg/dL
Up to a three-digit (numeric) value representing the participant’s
fasting glucose level in mg/dL
Glucose values that are between 037 and 050 mg/dL or 275 and 571
mg/dL will be flagged for quality checks and program verification.
Values outside 037-571 will be considered errors. See Appendix B
for the procedure for validating out-of-range values
Example: 90 mg/dL = 090
777 Inadequate blood
sample
Glucose measurement was attempted, but results were not obtained
due to technical difficulties or errors
See Appendix B for the procedure for documenting the reason that
the measurement was not obtained
This may include issues such as (1) two or more failed venipuncture
attempts; (2) insufficient amount of blood, type of test tube; (3)
invalid Cholestech readings due to very high/low values; (4) sample
submitted to laboratory, test not done due to erroneous or missing
laboratory request or other paperwork
This value will be flagged as an error if A1C is also invalid
888 Client refuseda
Participant refuses to have her blood drawn for glucose
measurements
If the participant refuses to go to the lab, the participant can be
considered to have refused
If the participant does not go to the scheduled lab appointment after
follow-up has been attempted, the participant can be considered to
have refused
This value will be flagged as an error if A1C is also invalid
999 No measurement
recordeda
No glucose measurement was taken for record
Non-fasting participants should always have this value
This value will be flagged as an error if A1C is also invalid
ANALYSIS AND USE
To identify participants who have pre-diabetes and diabetes
To assist in determining diabetes control and management
To use blood glucose or A1C percentage to accurately assess a participant’s diabetes status
To provide data element required to determine participant’s cardiovascular risk
To understand the overall rate of diabetes among the WISEWOMAN population
WISEWOMAN MDE Manual
Edition 18.3
65
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection form
completed by the provider. They are provided for funded program use only.
Glucose must be a fasting measurement. Programs may record both a glucose and A1C
measurement for a participant. Having values for both Glucose and A1C will not result in an
error.
In cases where the Cholestech machine indicates a reading of less than 37 mg/dL, the
guidance is to code the participant’s glucose as 037. Such a reading can identify an imminent
danger and requires urgent care.
A valid glucose measurement or A1C measurement at screening is required for a record to
count as a complete record.
Values are considered invalid for the glucose variable if: (1) participant is fasting and glucose is
left blank or coded as ‘777 Unable to obtain,’ ‘888 Client refused, or ‘999 No measurement
recorded, or is outside of the valid range (037-571 mg/dl), or (2) participant is not fasting.
Values are considered invalid for A1C variable if: (1) it is left blank, coded as ‘7777 Unable to
obtain,’ ‘8888 Client refused, or ‘9999 No measurement recorded,’ or is outside of the valid
range (02.8-16.2 mg/dL).
If exceptional circumstances do not allow Glucose measurement, these reasons should be
documented in the Validation of Data form as instructed in Appendix B.
*Complete require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
66
Item 15b: A1C*
A1C Percentage
This variable indicates the participant’s A1C percentage (if measured).
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
4
Justification:
Right
Field Length:
4
Beginning Position:
184
Leading Zeros:
Yes
Valid Range:
Static Field:
No
02.8-16.2; cannot be blank if
Glucose is blank and TYPE is 1 or 2
(baseline screening or rescreening)
SOURCE
Not applicable; health screening measurement
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
A1C percentage
Numeric value representing the participant’s A1C percentage. A1C
should be reported to one decimal point
If A1C was measured by another provider within the last 3 months,
it is acceptable to input the value if it is available
A1C values between 02.8% and 04.0% or 13.0% and 16.2% will be
flagged for quality checks and program verification. Values outside
02.8%-16.2% will be considered errors. See Appendix B for the
procedure for validating out-of-range values
Example: 8.5% = 08.5 (where the decimal place counts as part of
the variable length)
7777 Inadequate blood
sample
A1C measurement was attempted, but results were not obtained
due to technical difficulties or errors
This value will be flagged as an error if glucose is also invalid
8888 Client refuseda
Participant refuses to have an A1C test
If a participant refuses to go to the lab, the participant can be
considered to have refused
If a participant does not go to the scheduled lab appointment after
follow-up has been attempted, the participant can be considered to
have refused
This value will be flagged as an error if glucose is also invalid
9999 No measurement
recordeda
No A1C measurement was taken or recorded
This value will be flagged as an error if glucose is also invalid
To identify participants who have diabetes and refer them for medical management
To identify participants who have higher-than-optimal A1C levels and would benefit from
preventive services such as lifestyle programs
To assist in determining diabetes control and management
To assess the cardiovascular disease risk factors in the WISEWOMAN population
To provide data element required to determine participant’s cardiovascular risk score
aCodes and response options highlighted in gray should not appear on the data collection forms
OTHER
completed by the provider. They are provided for funded program use only.
INFORMATION
Participants with A1C percentage values greater than or equal to 6.5% are considered diabetic.
Participants with A1C percentage values less than 6.5% but greater than or equal to 5.7% are
considered pre-diabetic.
Programs may record both a glucose and A1C measurement for a participant. Having values for
both Glucose and A1C will not result in an error.
A1C measurement or glucose measurement at screening is required for a record to be a
complete record. If both Glucose and A1C are blank or coded as ‘777 Unable to obtain,’ ‘888
Client refused, or ‘999 No measurement recorded, or are outside of the valid range (Glucose:
37-571 mg/dL; A1C: 2.8-16.2%), the record will not count as a complete record. If exceptional
circumstances do not allow A1C measurement, these reasons should be documented in the
Validation of Data form as instructed in Appendix B.
Note that WISEWOMAN does not designate an alert value for A1C, because the A1C value
itself is a three-month average and is not accurate enough to identify that an individual’s life is in
imminent danger and requires urgent care.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
ANALYSIS AND USE
WISEWOMAN MDE Manual
Edition 18.3
67
Item 16a: BPAlert
FORMAT
Is a medical follow-up for blood pressure reading necessary?
This variable indicates whether medical follow-up for a participant’s alert level blood pressure is
medically necessary, as indicated by a SBP greater than 180 mmHg or DBP greater than 120
mmHg.
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
1
Beginning Position:
188
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be blank if
TYPE is 1, 2, 3 or 4 (baseline
screening, rescreening or follow-up)
SOURCE
JNC7 and American Heart Association 2017 guidelines
DENOMINATOR
POPULATION
Participants who have an alert level blood pressure value are included in the denominator
VALUES AND
DESCRIPTION
1
Medically necessary
Medical follow-up for blood pressure is medically necessary
2
Not medically needed
Medical follow-up for blood pressure is not medically
necessary
3
Medically necessary followup appointment declined
Medical follow-up for blood pressure is medically necessary
but participant failed to attend follow-up appointment
8
Client refused workupa
Participant had an alert level blood pressure reading but
refused workup
9
No answer recordeda
No answer recorded. This value will be flagged as an error.
ANALYSIS AND USE
To assess whether participants with alert level blood pressure readings are receiving a workup
To assist in determining hypertension (high blood pressure) management, and control
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
A participant is classified as having an alert blood pressure reading if her systolic blood
pressure reading measured during the screening (12b: SBP, positions 1 – 3) is greater than 180
mmHg or if her diastolic blood pressure reading at screening (12c: DBP, positions 1 – 3)) is
greater than 120 mmHg.
“3 Medically necessary follow-up appointment declined” should be used when a client had an
alert value and was scheduled to follow-up with a medical provider in within 7 days, however,
she did not show-up for the appointment..
“8 Client refused workup” should be used when the client had an alert value, however, she
refused to schedule a follow-up with a medical provider.
WISEWOMAN MDE Manual
Edition 18.3
68
Item 16b: BPDiDate
What is the date of the medically necessary follow-up appointment?
This variable indicates the follow-up appointment date for a participant with an alert level blood
pressure reading.
FORMAT
Type:
Numeric
Other Format:
MMDDCCYY
Item Length:
8
Justification:
Right
Field Length:
8
Beginning Position:
189
Leading Zeros:
Yes
Valid Range:
Static Field:
No
Valid date; cannot be blank if TYPE
is 1, 2, 3 or 4 (baseline screening,
rescreening or follow-up)
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
Participants who have an alert level blood pressure value are included in the denominator
VALUES AND
DESCRIPTION
Medically Necessary
Follow-up
Appointment Date
ANALYSIS AND USE
To assess whether providers are performing timely workups for participants with alert level
blood pressure values
To determine whether programs are meeting the guideline of workups within one week of the
screening for alert participants
To assist in determining hypertension (high blood pressure) prevention, management, and
control
OTHER
INFORMATION
A participant is classified as having an alert blood pressure reading if her systolic blood
pressure reading measured at the screening visit (12b: SBP, positions 1 - 3) is greater than 180
mmHg or if her diastolic blood pressure reading measured at the screening visit (12c: DBP,
positions 1 - 3) is greater than 120 mmHg.
Only participants who are coded as having an alert blood pressure reading (16a: BPAlert = ‘1
Medically necessary,’ 3 Medically necessary – follow-up appointment declined,‘ 8 Client refused
workup,’ or ‘9 Workup not completed’) should have a blood pressure diagnostic exam date.
However, in cases where blood pressure readings are just under the alert threshold (SBPs >
165 and ≤ 180 and DBPs >110 and ≤ 120) a valid BPDiDate will result in a quality check rather
than an error. If a participant with an alert blood pressure value has a blood pressure workup
status (16a: BPAlert) coded as ‘‘1 Medically necessary,’ this field must be completed with the
date of the diagnostic exam.
If a participant with an alert blood pressure value has a blood pressure workup status (16a:
BPAlert) coded as ‘3- Medically necessary- follow-up appointment declined’ or ‘8 Client refused
workup,’ this field should contain the date of refusal as defined by program protocol.
If a participant with an alert blood pressure value has a blood pressure workup status (16a:
BPAlert) coded as ‘9 Workup not completed,’ this field should contain the date that the program
considered the participant lost to follow-up as defined by program protocol
WISEWOMAN MDE Manual
Edition 18.3
Valid date in MMDDCCYY format
If follow-up information is provided for this referral, the workup date
can be entered
Example: September 10, 2018 = 09102018
69
4. RISK REDUCTION COUNSELING MDE SPECIFICATIONS
This section provides recipients with the information necessary to support collection and
reporting of the Risk Reduction Counseling MDE, which must be done according to the
specifications provided in this section of the manual. Risk reduction counseling should be
provided at all screenings. 4
For a record to be counted as a Complete screening, it must have valid values for required
MDEs. Definitions of complete screenings are provided in Appendix A.
This section begins with a summary of the required variable (Subsection a) and then provides
the technical specifications for the variable (Subsection b).
4
Values left blank are considered invalid values for risk reduction counseling completion date.
WISEWOMAN MDE Manual
Edition 18.3
70
a. Summary of Risk Reduction Counseling MDEs
Item
Number
17a
Variable Name
RRCComplete
WISEWOMAN MDE Manual
Edition 18.3
Beginning
Position
Variable Label
197
Risk reduction counseling completion date
71
Type
Numeric
b. Risk Reduction Counseling MDE Specifications
Item 17a:
RRCComplete*
Risk Reduction Counseling Completion Date
This variable indicates the date that risk reduction counseling was completed.
FORMAT
Type:
Numeric
Other Format:
MMDDCCYY
Item Length:
8
Justification:
Right
Field Length:
8
Beginning Position:
197
Leading Zeros:
Yes
Valid Range:
Static Field:
No
Valid date; cannot be blank if TYPE
is 1, 2, 3 or 4 (baseline screening,
rescreening or follow-up)
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Risk reduction counseling
follow-up date
Valid date in MMDDCCYY format
Date must occur within the submission period
Example: September 10, 2018 = 09102018
88888888 Participant refused
further program contacta
Participant refused further program contact
This value will be flagged as a quality check
99999999 Participant lost to
follow-upa
Provider made three attempts to follow-up with participant but
participant lost to follow-up.
This value will be flagged as a quality check
ANALYSIS AND USE
OTHER
INFORMATION
To determine the date of a completed risk reduction counseling session, which should be
provided for all screenings
To facilitate analysis of changes in risk reduction counseling provision over time
aCodes and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
If risk reduction counseling is completed on the same date as the clinical assessment, the same
date should be recorded for 12a: BPDate and 17a: RRCComplete.
If laboratory results are not available at the time of the screening visit to provide risk reduction
counseling, this field should be used to indicate the date on which risk reduction counseling was
completed.
If RRCComplete is blank the record will not count as a complete record.
*Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
72
5. HEALTHY BEHAVIOR SUPPORT SERVICES MDE SPECIFICATIONS
This section provides recipients with the information necessary to support collection and
reporting of Lifestyle Program/Health Coaching MDEs as well as referrals to communitybased tobacco cessation resources which must be done according to the specifications
provided in this section of the manual.
For a record to be counted as a Complete or BP+ screening, it must have valid values for
required MDEs. Definitions of complete and BP+ screenings are provided in Appendix A.
An LSP/HC contact is counted if the following MDE variables in a record have valid values:
date of LSP/HC session, LSP/HC ID, and date of referral. 5 Recipients may report LSP/HC
data that do not meet these requirements, but they will not be counted as an LSP/HC
session, analyzed in data reports generated by CDC, or counted in the related performance
measure unless additional documentation is provided.
This section begins with a summary of the 7 required variables (Subsection a) and then
provides the technical specifications for each variable (Subsection b).
5 If a valid date of an LSP/HC session is provided, values left blank for LSPHCID or that are not included on the current list
of CDC-approved LSP/HC IDs, are considered invalid values. If the date of an LSP/HC session is blank then the LSP/HC
contact will not be counted.
WISEWOMAN MDE Manual
Edition 18.3
73
a. Summary of Healthy Behavior Support Services MDEs
Item
Number
Variable
Name
Beginning
Position
Variable Label
Type
18a
RefDate
205
Lifestyle Program (LSP) / Health Coaching (HC)
referral date
Numeric
19a
LSPHCRec
221
Number of Lifestyle Program (LSP) / Health
Coaching (HC) Sessions Received by the
Participant Associated with the Current Screening
Numeric
19b
Intervention
223
Date of Lifestyle Program (LSP) / Health Coaching
(HC) session)
Numeric
19c
LSPHCID
351
Lifestyle Program (LSP) / Health Coaching (HC) ID
Character
20a
TobResDate
511
Date of referral to Tobacco Cessation Resource
Numeric
20b
TobResType
535
Type of Tobacco Cessation Resource
Numeric
20c
TResComp
538
Tobacco Cessation activity completed
Numeric
WISEWOMAN MDE Manual
Edition 18.3
74
b. Healthy Behavior Support Services MDE Specifications
Item 18a: RefDate*
Lifestyle Program (LSP) / Health Coaching (HC) Referral Date
This variable indicates the date that a referral to a LSP/HC occurred.
FORMAT
Type:
Numeric
Other Format:
MMDDCCYY
Item Length:
8
Justification:
Right
Field Length:
16
Beginning Position:
205
Leading Zeros:
Yes
Valid Range:
Valid date
Static Field:
No
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Lifestyle Program/Health
Coaching Referral Date
Valid date in MMDDCCYY format
Date must occur within the submission period
Example: September 10, 2018 = 09102018
8888888888888888
refused to answer
Participant refused LSP/HC referral.
This value will be flagged as a quality check.
ANALYSIS AND USE
To determine the date of the referral to an LSP/HC
To assist in determining whether the participant has received a referral to a LSP/HC
To assist in determining the number of LSP/HC referrals per participant
To facilitate analysis of changes in LSP/HC referrals over time
OTHER
INFORMATION
To calculate the number of LSP or HC referrals per participant, the number of LSP/HC
referral dates is counted for each unique participant ID (3a: EncodeID).
For each screening, up to two referral dates can be recorded in this field and the Refdate
should be recorded in the order in which the referrrals occurred.
If a provider attempts to refer a participant to an LSP/HC but the participant refuses to be
referred, a value of 8888888888888888 should be entered.
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
75
Item 19a: LSPHCRec*
Number of Lifestyle Program (LSP) / Health Coaching (HC) Sessions Received by the
Participant Associated with the Current Screening
This variable indicates the number of LSP/HC sessions the participant has received during the
current screening prior to a subsequent follow-up screening or rescreening.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
2
Justification:
Right
Field Length:
2
Beginning Position:
221
Leading Zeros:
Yes
Valid Range:
Static Field:
No
Cannot be blank if
Refdate is valid
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Number of Sessions
ANALYSIS AND USE
To track the number of LSP/HC sessions that the participant has received
Value representing the number of LSP/HC sessions the participant
has received associated with the current screening
Example: 6 visits = 06
OTHER
INFORMATION
The number of LSP and HC sessions the participant has received during the current screening
(prior to a subsequent follow-up screening or rescreening) should be provided in this field.
During the creation of the analytic file, CDC will check that the number of LSP/HC sessions
received by the participant is equal to the number of unique LSP/HC dates provided during the
cooperative agreement period. Sessions will not count unless the record also contains a valid
LSP/HC referral date (18a: RefDate).
*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.
WISEWOMAN MDE Manual
Edition 18.3
76
Item 19b: Intervention
Date of Lifestyle Program (LSP) / Health Coaching (HC) Session
For LSP/HC records, this variable indicates the date that the LSP/HC session occurred.
FORMAT
Type:
Numeric
Other Format:
MMDDCCYY
Item Length:
8
Justification:
Right
Field Length:
128
Beginning Position:
223
Leading Zeros:
Yes
Valid Range:
Valid date
Static Field:
No
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
All LSP/HC sessions among WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Lifestyle Program/Health
Coaching Session Date
ANALYSIS AND USE
To determine the date of the LSP/HC session
To assist in determining whether the participant has received an LSP/HC session
To assist in calculating the number of LSP/HC sessions per participant
To assess whether participants with risk factors receive LSP/HC services
To assess changes in risk profile between participants who participate in the LSP/HC and
participants who do not
OTHER
INFORMATION
To calculate the number of LSP or HC sessions per participant, the number of LSP/HC session
dates is counted for each unique participant ID (3a: EncodeID).
Programs can enter up to 16 LSP/HC intervention dates per screening. If additional sessions
are provided to a participant before a subsequent follow-up screening or recsreening, these
sessions should be recorded in the Supplemental LSP/HC Session form, as described in
Appendix B.
LSP/HC intervention dates should be recorded on the screening record during which the
referral was made. For example, if a referral to health coaching was made during the baseline
screening, the intervention dates should be recorded on this record, until a new referral is
made during a subsequent screening.
WISEWOMAN MDE Manual
Edition 18.3
77
Valid date in MMDDCCYY format
Date must occur within the submission period
Example: September 10, 2018 = 09102018
Item 19c: LSPHCID
Lifestyle Program (LSP) / Health Coaching (HC) ID
This variable indicates which LSP/HC was used.
FORMAT
Type:
Character
Other Format:
N/A
Item Length:
10
Justification:
Left
Field Length:
160
Beginning Position:
351
Leading Zeros:
N/A
Valid Range:
Static Field:
No
Valid code for an LSP/HC;
cannot be blank if valid date
provided for Intervention
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
All LSP/HC sessions among WISEWOMAN participants with a Complete/BP+ baseline
screening
VALUES AND
DESCRIPTION
Lifestyle Program ID
Health Coaching ID
ANALYSIS AND USE
To assess the number of WISEWOMAN participants who receive an LSP/HC session from each
WISEWOMAN LSP/HC provider
To describe differences in participant demographics or other characteristics by LSP/HC provider
To identify the number of LSP/HC providers in a given geographic area
OTHER
INFORMATION
If the participant receives an LSP or HC session, the LSP/HC ID should be provided in this field.
WISEWOMAN MDE Manual
Edition 18.3
Value representing the ID code of the LSP as assigned
Value representing the ID code of the HC as assigned
78
Item 20a: TobResDate
Date of Referral to Tobacco Cessation Resource
This variable indicates the date that the referral to a tobacco cessation resource occurred.
FORMAT
Type:
Numeric
Other Format:
MMDDCCYY
Item Length:
8
Justification:
Right
Field Length:
24
Beginning Position:
511
Leading Zeros:
No
Valid Range:
Static Field:
No
Valid date; cannot be
blank if Smoker=1
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
WISEWOMAN participants with a Complete/BP+ baseline screening who identify themselves
as current smokers
VALUES AND
DESCRIPTION
Tobacco Cessation
Resource Referral Date
Valid date in MMDDCCYY format
Date must occur within the submission period
Example: September 10, 2018 = 09102018
888888888888888888888 Participant refused tobacco cessation resource referral
This value will be flagged as a quality check if the participant
888 refused to answer
identifies as a current smoker
ANALYSIS AND USE
To document the date of a referral to tobacco cessation resource
To assist in tracking receipt of tobacco cessation resource
OTHER
INFORMATION
To calculate the number of tobacco cessation resources referrals per participant, the number
of tobacco cessation resource referral dates is counted for each unique participant ID (3a:
EncodeID).
If a participant is referred to one or more tobacco cessation resources, the date of referral
(Item 20a:TobResDate), type of resource the participant was referred to (Item 20b:
TobResType), and completion status for the resource at the end of the current screening
(Item 20c: TResComp) should be recorded for each referral. The positions for the type of
resource and completion status of resource for each referral should align with the position of
the date of referral. For example, if a participant receives two referrals during the screening
period, the date of referral, type of resource, and completion status for the second referral
should be provided in the second position for each item.
If a provider attempts to refer a participant to tobacco cessation resource but the participant
refuses to be referred, a value of 888888888888888888888888 should be entered.
WISEWOMAN MDE Manual
Edition 18.3
79
Item 20b: TobResType
Type of Tobacco Cessation Resource
This variable indicates the type of tobacco cessation resource that the participant was referred
to.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
3
Beginning Position:
535
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank if valid date provided
for TobResDate
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
WISEWOMAN participants with a Complete/BP+ baseline screening who identify themselves
as current smokers
VALUES AND
DESCRIPTION
1
Quit line
Participant was referred to a proactive tobacco quit line
2
Community-based
tobacco program
Participant was referred to a community-based tobacco
program
3
Other tobacco cessation
resources
Participant was referred to other tobacco cessation
resources
4
Internet-based tobacco
program
Participant was referred to an internet-based tobacco
program
9
No answer recordeda
No answer was recorded
This value will be flagged as an error if a valid date is
provided for TobResDate
ANALYSIS AND USE
To determine the number of smokers that received a referral to tobacco cessation resource
To determine how frequently different types of tobacco cessation resources are being used
within and across programs
To compare the smoking status at follow-up and rescreening of women who were linked to
tobacco cessation resources versus those who were not
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection
forms completed by the provider. They are provided for funded program use only.
WISEWOMAN MDE Manual
Edition 18.3
80
Item 20c: TResComp
Tobacco Cessation Activity Completed
This variable indicates whether the participant completed tobacco cessation activity.
FORMAT
Type:
Numeric
Other Format:
N/A
Item Length:
1
Justification:
Right
Field Length:
3
Beginning Position:
538
Leading Zeros:
No
Valid Range:
Static Field:
No
See values; cannot be
blank if valid date
provided for TobResDate
SOURCE
Not applicable; WISEWOMAN-specific variable
DENOMINATOR
POPULATION
WISEWOMAN participants with a Complete/BP+ baseline screening who identify themselves as
current smokers
VALUES AND
DESCRIPTION
1
Yes – Completed tobacco
cessation activity
Participant completed tobacco cessation activity
2
No – Partially completed
tobacco cessation activity
Participant partially completed tobacco cessation activity
3
No – Discontinued from
tobacco cessation activity
when reached
Participant decided to discontinue from tobacco cessation
counseling when contacted by the tobacco cessation
resource
4
No – Could not reach to
conduct tobacco cessation
activity
Participant could not be reached when contacted by the
tobacco cessation resource
9
No answer recordeda
No answer was recorded
This value will be flagged as an error if a valid date is
provided for TobResDate
ANALYSIS AND USE
To determine the number of smokers that participated in tobacco cessation activities
To compare the smoking status at follow-up and rescreening of women who were linked to
tobacco cessation resources versus those who were not linked to tobacco cessation resources
OTHER
INFORMATION
aCodes
and response options highlighted in gray should not appear on the data collection forms
completed by the provider. They are provided for funded program use only.
If a participant receives a referral to a tobacco cessation resource but the completion status of
the resource is unknown, TResComp should be coded as 2 (No – Partially completed tobacco
cessation activity) and updated accordingly if the completion status becomes available.
WISEWOMAN MDE Manual
Edition 18.3
81
APPENDIX A:
SCREENING DEFINITIONS AND SUBMISSION GUIDANCE
This Appendix provides screening definitions and submission guidance for MDE files,
including those related to format, procedures, and security. Submissions will not be
processed if recipients fail to follow the guidelines provided below.
Data Submission Guidance
Recipients must submit data to CDC through the Data Management System 3.0. For
additional guidance on data submission, refer to the Data Management System Quick
Reference Guide, available on the WISEWOMAN Data Management System website.
a. Screening Definitions
Table A.1 provides an overview of WISEWOMAN screening definitions. For MDE 18.3,
recipients should report each baseline screening, follow-up screening, and rescreening as a
separate row in their data file for the reporting period. CDC will use unique participant
identifier (EncodeID), month and year of birth (MYB), and state/tribal FIPS code (STFIPS) to
identify each woman within the data, and the Type field and the clinical assessment date
(BPDate) to determine whether each record represents a baseline screening, rescreening, or
follow-up screening for that woman.
Table A.1. Screening Definitions
Type
Description
Line Layout of Data
Baseline Screening
Initial participant screening; establishes starting point
for WISEWOMAN program
First line
Follow-up Screening
Post healthy behavior support service (must occur 3
months and no later than 11 months after a
participant’s baseline screening or last rescreening
and within 4 to 6 weeks after completion of the
LSP/HC)
Second line
Re-screening
Subsequent screenings occurring 11-18 months after
a participant’s baseline screening or last rescreening
Third line
CDC will determine whether each submitted baseline screening, rescreening, and follow-up
screening record will be counted as complete or blood pressure plus (BP+) using the criteria
described below, and further detailed in Table A.2.
A complete record, at minimum, includes valid values for the following MDEs: 1
1
•
Administrative and Demographic items (1a-3f)
•
Disease Status and Health History (4a-4b)
•
Medication Use, Aspirin Use, and Medication Adherence (5a-5c)
•
Nutrition (7a – 7e) and Physical Activity (8a)
•
Smoking Status (9a)
•
Stress (10a)
Invalid values are defined in Table A.2 below and in the Edits documentation, which is available in the Data Management
System 3.0.
WISEWOMAN MDE Manual
Edition 18.3
A.1
•
Height (11a) / Weight (11b)
•
Clinical Assessment Date (12a)
•
Blood Pressure (12b-12c)
•
Fasting Status (13a)*
•
Cholesterol (14a-14c)*
•
Blood Sugar (15a or 15b)*
•
Risk Reduction Counseling (17a)
•
LSP/HC Referral Date (18a)
•
LSP/HC Received (count) (19a)
A BP+ record, at minimum, includes valid values for the following MDEs:
•
Administrative and Demographic items (1a-3f)
•
Disease Status and Health History (4a-4b)
•
Medication Use, Aspirin Use, and Medication Adherence (5a-5c)
•
Smoking Status (9a)
•
Height (11a) / Weight (11b)
•
Clinical Assessment Date (12a)
•
Blood Pressure (12b-12c)
•
Fasting Status (13a)*
•
Cholesterol (14a-14c)*
•
LSP/HC Referral Date (18a)
•
LSP/HC Received (count) (19a)
*Labs may not be medically required for certain participants at follow-up screening, therefore,
will not be included in the definition of complete and BP+ at this type of visit.
b. Data Conventions
This section provides an overview of the data file format and layout for the MDEs. It defines
data length and position and describes the types of MDE data. The data conventions
described here represent the raw file format and layout of MDEs that recipients must follow
when submitting data to the Data Management System 3.0 website.
•
Data Types. There are several data types, including date, geographic, character, and
numeric.
o Dates have the format MMDDCCYY.
MM represents the month and has a range of 01–12; use leading zeros
with months 01–09. If month is missing, month is blank (as indicated by a
period [.] in each blank position).
WISEWOMAN MDE Manual
Edition 18.3
A.2
DD represents the day of the month and has a range of 01–31; use
leading zeros with days 01–09. If day is missing, day is blank (as
indicated by a period [.] in each blank position).
CC represents the century and has a range of 19–20. If century is
missing, century is blank (as indicated by a period [.] in each blank
position).
YY represents the year and has a range of 00–99; use leading zeros with
years 00–09. If year is missing, year is blank (as indicated by a period [.]
in each blank position).
o Geographic data elements are state/tribal FIPS code, ANSI county code, county
of residence, and ZIP code of residence. These are character variables, and
require leading zeros to fill the field length.
o Character data elements are composed of letters of the alphabet, numbers, and
special characters. These are left-justified, and in cases where the value does
not fill the entire field length, extra spaces in the length should be left blank (as
indicated by a period [.] in each blank position). If there are no data for a given
MDE, all positions should either be filled with a period [.] or left blank.
o Numeric data elements are composed of numbers, minus signs, and decimal
points. Numeric data elements are right-justified. If numbers are expected to the
right of the decimal, the number of decimal places required is indicated in the
MDE specification. In cases where the value does not fill the entire field length,
leading zeros should be used to fill the field length.
•
Item Length. Item length represents the number of characters (i.e., letters of the
alphabet, numbers, and special characters) for one entry of the item.
•
Field Length. If the data element may be collected more than one time during the
screening, such as Intervention which captures the date of an LSP or HC session, the
field length will allow for multiple entries of this data element.
•
Static Field. If the field is static, it should not be updated or modified after the first time
the element is recorded. For example, month and year of birth is considered a static
field because it is not expected that a participant’s date of birth would change over
time. However, blood pressure measurements are not static fields since it could
change over time.
•
Beginning Position. Position is the location in the record of a data element. The
length and position of each data element are provided in the MDE specifications.
The table below summarized the position, item length, and field length for the MDE variables.
Cells with an ‘X” indicate that an MDE variable is required to be valid for either a baseline
screening, rescreening, or follow-up screening to count as either complete record or BP+
record.
WISEWOMAN MDE Manual
Edition 18.3
A.3
Table A.2. MDE Item Format and Invalid Values
Position
Item
Number
MDE Name
Item
Length
Field
Length
Complete
BP+
Invalid Values
(for required items)
1
1a
StFips
2
2
X
X
Blank or not an allowable value*
3
1b
HdANSI
5
5
X
X
Blank**
8
1c
EnrollSiteID
5
5
X
X
Blank**
13
1d
ScreenSiteID
10
10
X
X
Blank**
23
2a
TimePer
1
1
X
X
Blank, out of range, or not an allowable value* if the record is a
baseline screening
24
2b
Nscreen
1
1
X
X
Blank
25
2c
Type
1
1
X
X
Blank, coded as missing (9), or not an allowable value*
26
2d
Navigation
1
1
X
X
Blank or not an allowable value*
27
3a
EncodeID
15
15
X
X
Blank
42
3b
ResANSI
5
5
X
X
Blank**
47
3c
Zip
5
5
X
X
Blank, coded as missing (99999) or not a valid 5-digit zip code
52
3d
MYB
6
6
X
X
Blank
58
3e
Latino
1
1
X
X
Blank, coded as missing (9), or not an allowable value*
X
X
Blank, coded as missing (9), or not an allowable value*
Exception: Values of missing (9) are permitted if the participant is
Latino
59
3f
Race1
1
1
60
3g
Race2
1
1
61
3h
Education
1
1
62
3i
Language
2
2
64
4a
SRC
3
3
X
X
First, second, or third position blank, coded as missing (9), or not an
allowable value*
67
4b
SRHA
6
6
X
X
First, second, third, fourth, fifth, or sixth position blank, coded as
missing (9) or not an allowable value*
73
5a
Meds
4
4
X
X
First, second, third, or fourth position blank, coded as missing (9) or
not an allowable value*
77
5b
Aspirin
1
1
X
X
Blank, coded as missing, or not an allowable value*
X
Any set of two positions blank, coded as missing (99), out or range
(>07), incorrectly coded as not applicable (55) for participants who
were prescribed medication, or incorrectly coded as 01 through 07
days for participants who were not prescribed medication
78
5c
MedAdhere
6
6
84
5d
Monitored
8
24
WISEWOMAN MDE Manual
Edition 18.3
X
A.4
Position
Item
Number
MDE Name
Item
Length
Field
Length
Complete
BP+
Invalid Values
(for required items)
108
6a
BPHome
1
1
109
6b
BPFreq
1
1
110
6c
BPSend
1
1
111
7a
FruitVeg
2
2
X
Blank, coded as missing (99), or out of range (>65)
113
7b
Fish
1
1
X
Blank, coded as missing (9), or not an allowable value*
114
7c
Grains
1
1
X
Blank, coded as missing (9), or not an allowable value*
115
7d
Sugar
1
1
X
Blank, coded as missing (9), or not an allowable value*
116
7e
SaltWatch
1
1
X
Blank, coded as missing (9), or not an allowable value*
117
7f
AlcFreq
2
2
119
7g
AlcDay
2
2
121
8a
PA
4
4
X
Blank, coded as missing (9999)
125
9a
Smoker
1
1
X
126
10a
PHQ
2
2
X
128
11a
Height
2
2
X
X
Blank or coded as unable to obtain (77), refused (88), missing (99),
or out of range (<48; >76)
130
11b
Weight
3
3
X
X
Blank, coded as missing (999), or out of range (<74; >460)
133
11c
Waist
2
2
135
12a
BPDate
8
8
X
X
Blank or illogical entry (e.g., date is in the future or is a non-numeric
value)
143
12b
SBP
3
12
X
X
Position 1, 2, and 3 are blank or coded as unable to obtain (777),
refused (888), missing (999), or out of range (<74; >260)
155
12c
DBP
3
12
X
X
Position 1, 2, and 3 are blank or coded as unable to obtain (777),
refused (888), missing (999), or out of range (<002; >156)
167
13a
Fast
1
1
X****
X****
Blank, coded as missing (9) if Type = 1 or 2
168
14a
TotChol
3
3
X****
X****
Blank, coded as unable to obtain (777), refused (888), missing (999),
or out of range (<44; >702) if Type = 1 or 2
171
14b
HDL
3
3
X****
X****
Blank, coded as unable to obtain (777), refused (888), missing (999),
or out of range (<7; >196) if Type = 1 or 2
X****
Blank, coded as unable to obtain (777), refused (888), missing
(999), or out of range (<20 or >380) if Type = 1 or 2
Note: Any value will be invalid for nonfasting participants who are on
lipid-lowering therapy, have a history of high cholesterol, or have a
triglyceride level >400 mg/dL
174
14c
LDL
WISEWOMAN MDE Manual
Edition 18.3
3
3
X****
A.5
X
Blank, coded as missing (9), or not an allowable value*
First or second position is blank, coded as missing (9), or not an
allowable value*
Position
Item
Number
MDE Name
Item
Length
Field
Length
Complete
Invalid Values
(for required items)
BP+
177
14d
Trigly
4
4
181
15a
Glucose***
3
3
X****
184
15b
A1C***
4
4
X****
188
16a
BPAlert
1
1
189
16b
BPDiDate
8
8
197
17a
RRCComplete*****
8
8
X
205
18a
RefDate
8
16
X
X
Illogical entry (e.g., date is in the future)
221
19a
LSPHCRec
2
2
X
X
Blank if referral date is valid
223
19b
Intervention
351
19c
LSPHCID
511
20a
535
40
31
8
128
10
160
TobResDate
8
24
20b
TobResType
1
3
538
20c
TResComp
1
3
540
End
Complete String
-
Count
Participant is fasting and glucose is blank or coded as unable to
obtain (777), refused (888), missing (999) or out of range (<37 or
>571), and A1C is blank or coded as unable to obtain (7777),
refused (8888), missing (9999) or out of range (<2.8 or >16.2) and
Type = 1 or 2; OR participant is not fasting and A1C is blank or
coded as unable to obtain (7777), refused (8888), missing (9999) or
out of range (<2.8 or >16.2) and Type = 1 or 2
Blank
* Values are considered not allowable if they are not one of the listed response categories for categorical items
** A string of zeros is not a valid response for this item.
*** Only A1c OR Glucose is required for Complete screenings (baseline and rescreening only), recipients do not need to collect both
**** Labs may not be medically required for certain participants at follow-up screening, therefore, will not be included in the definition of complete and BP+ at this visit
***** Program flow requires Risk Reduction Counseling at every screening. Date does not need to be entered in MDE file for BP+
WISEWOMAN MDE Manual
Edition 18.3
A.6
c. Submission Procedures
It is important to account for all WISEWOMAN services provided through funding dollars so
recipients must submit all data for every participant (e.g., Complete, BP+, and incomplete
records).
Please submit only one file containing all screening records. Recipients should upload their
submission to the DMS 3.0 as a fixed-format ASCII text file. MDEs must be recorded in the
locations identified in the MDE specifications. Each record in the file should represent data for
a unique screening visit (baseline screening, follow-up screening, rescreening) with all
associated activities. The associated activities may include LSP and/or health coaching (HC)
contacts. Each data element must conform to the format and values as specified. Files must
include data for the appropriate time period.
For recipients choosing to submit Supplemental LSP/HC data for lifestyle program and health
coaching referrals and sessions that exceed the capacity of the MDE file, please read the
instructions which can be found in TA Resources under the Library tab inside DMS 3.0 and in
Appendix B. Files should be named using the format PPYYMM where PP is the program
abbreviation and YYMM is the date of the submission. YY is the two-digit year, and MM is the
month from 01 to 12. Recipients should use leading zeros when specifying years and months
between 01 and 09. An example of a valid file name is PA1912.
Recipients are encouraged to begin validating their data at least four weeks prior to the
submission datehelp and can be reached at [email protected].
Data managers for each recipient have been provided with a username and password to log
into the web-based WISEWOMAN Data Management System 3.0. Other recipient staff will be
provided with a separate username and password upon request. Prior to submission,
recipients should prepare bulk data files as instructed for the relevant period and run it
through the online validation tool to identify errors and quality checks. These errors and
quality checks should be addressed to the extent possible prior to submission. See Appendix
B for forms that recipients may submit along with their MDE data file.
As the data contractor prepares the analytic file after programs’ final submissions, data
issues may be identified for immediate correction. In these instances, project officers will
notify programs that there are data issues for correction and will follow up with programs
about making these corrections. The project officer will act as a liaison to the data contractor
on these issues. Programs will resubmit corrected data through the WISEWOMAN website
and notify their project officers.
d. Data Confidentiality and Security
This section describes the data confidentiality and security guidelines for preparing and
submitting MDE data. Data and documents submitted via the WISEWOMAN website will be
encrypted during transmission. Programs must not send information that will allow
participants to be identified and must use encoded identifiers and so on to uniquely identify
participants’ data. In addition, data submissions must be de-identified pursuant to the Health
Insurance Portability and Accountability Act of 1996 (HIPAA).
WISEWOMAN MDE Manual
Edition 18.3
A.7
MDE data are “limited data sets” in which all identifying information has been removed, with
the exception of encoded participant ID, county of residence, ZIP code of residence, birth
month and year, Hispanic origin, and race. The participant ID must not be linked to any other
external datasets containing personal information. Submissions must not include any of the
identifiers stipulated in HIPAA.
Recipients are expected to implement data security procedures that will secure participant
identifying and health information, including those related to back-up, hardcopy and electronic
storage, and transmission. Additional information about CDC data security procedures can be
requested.
WISEWOMAN MDE Manual
Edition 18.3
A.8
APPENDIX B:
DATA QUALITY AND VALIDATION
CDC is committed to ensuring that the data submitted are accurate, valid, reliable, and
complete, and provides recipients with several tools to help monitor and improve data quality.
This section describes three items: online validation through the Data Management System
3.0; data validation procedures and forms; and the method for calculating error rates. These
items together form a data quality system that allows the identification and
validation/correction of out-of-range values, improbable values, and missing data (unknown,
refused, and not obtained). It also provides an assessment of data quality through an error
rate calculation algorithm.
Validation of Data
Online validation will be available through the WISEWOMAN Data Management System 3.0.
Instructions for validating data are available in the WISEWOMAN Quick Reference Manual
resource in the“Documents” tab of the Data Management System 3.0.
CDC distinguishes between errors and quality checks using the following definitions.
•
Errors are out-of-range and missing values for variables that are critical to
assessment of program performance, management, and areas for improvement.
Responses that are not considered programmatically acceptable may also be defined
as errors.
•
Quality Checks are values that seem improbable but are still possible; should be
available but are unknown, refused, or unable to be obtained; are not required but are
missing; or are contrary to medical guidance. 1 Responses that may be clinically
problematic may also be highlighted for quality checks along with values that are
programmatically problematic, i.e., values that do not align with program guidance,
such as ages outside of 40-64 years.
Prior to data submission, programs should ensure that their data are validated. Programs are
encouraged to check on the validity of their data multiple times before the deadline to
maximize data quality. Whenever possible, errors should be corrected and quality check
values validated before the data are submitted to CDC.
As needed, the online validation provided on the web-based WISEWOMAN website will be
updated by the data contractor to reflect any changes in specifications and to account for
nuances discovered about the data. Any changes will be documented in the MDE manual
and edits documentation.
1 Valid values for items used to determine a complete or BP+ screening record are provided in Table A.2.
WISEWOMAN MDE Manual
Edition 18.3
B.3
Data Validation Procedures and Forms
Specific response options for some data elements require that recipients provide information
in addition to that in the MDE data files. This section describes the procedures and forms that
can be used to validate or explain values in the MDE data submitted, to provide explanation
for alerts not seen within seven days, to notify CDC of changes in participants’ unique IDs, to
make corrections to previous MDE data, and report on additional LSP/HC sessions.
Validation or Explanation of Values
When MDE values are flagged as errors, recipients can confirm these values to be valid or
provide further explanation about them using the Validation of Data form (recipients are not
required to provide further explanation for quality checks). This form can be completed on the
web-based WISEWOMAN Data Management System 3.0 at the time of MDE submission and
by the submission deadline.
Values for validation or explanation fall into the following general categories:
•
Out-of-range values. These will be identified as quality checks or errors. In general,
values that are highly unusual will be identified as quality checks, while values that are
nearly impossible or are not a response option for a categorical field will be identified
as errors. For example, heights less than 48 inches will be flagged as errors. Because
such a height would result in an error for this record, the program might confirm this
height by submitting an entry in the Validation of Data form and explaining the
circumstances of the error.
•
Responses coded as participant refused. Although participants are able to refuse
any question or clinical service, it may be appropriate to inform CDC why the program
has chosen to include a woman who refuses basic assessment or screening services
as a participant in the program.
•
Other. Other errors flagged for which the recipient would like to provide an
explanation.
Notification of Participant Unique ID Changes
If the participant unique ID number changes for one or more participants between
submissions, recipients must notify CDC of the change by submitting a Participant ID Change
Form, which details the participant unique IDs affected. This form can be completed on the
web-based WISEWOMAN Data Management System 3.0. Identifying these changes is
critical to accurately link records between periods and follow participant changes over time.
WISEWOMAN MDE Manual
Edition 18.3
B.4
Error Rate Calculation Method
This section provides the method used to calculate error rates. The WISEWOMAN website
will generate a validation report for immediate viewing through the online validation tool. The
report contains an error rate calculated for the entire submission. There are 59 variables,
which include variables with multiple components. These components sum up to a total of 72.
The error rate is calculated using the following formula:
1. Complete error score calculation:
= # of Errors / (# of Complete Records * 72 components)
2. BP+ error score calculation:
= # of Errors (excluding errors on the 10 MDEs not required for BP+) / (# of BP+ Records
* 62 components)
Notes:
− The number of components = 72 -10 = 62
− The 10 MDEs required for BP+ but not Complete include: FruitVeg, Fish, Grains,
Sugar, SaltWatch, PA, PHQ, Glucose, A1C, RRCComplete
− Errors on the 10 MDEs listed above should be excluded from the numerator
3. Weighted error score calculation:
(Complete Error Rate * (# Complete Records / # Complete & BP+ records)) +
(BP+ Error Rate * (# BP+ records / # Complete & BP+ records))
Programs can provide explanations for any errors by submitting to CDC the Validation of
Data form shown at the end of this Appendix. The calculation of the final error rate will be
conducted following the final submission and review of documentation provided by programs.
WISEWOMAN MDE Manual
Edition 18.3
B.5
Validation of Data Form
The Validation of Data Form should be filled out to validate or explain any values submitted.
These values will include mainly those flagged as errors. (See the Documents tab inData
Management System 3.0 for a list of errors and quality checks). CDC will review the
information provided in this form and consider these values in the calculation of the error rate.
Each value in the form (which is available on the web-based WISEWOMAN Data
Management System 3.0) should be reviewed and verified by your program staff. To fill out
this form, go to the Miscellaneous Forms tab of the Data Management System 3.0 and select
"Go to Validation of Data Form." Select "Create New Validation of Data record" for each MDE
item to be validated. The following information is needed for each record:
•
StFIPS. Provide your state or tribal code for the record to be validated/explained.
•
Validation Type. Identify whether the validation or explanation is for an error (E),
quality check (Q), or some other issue (O).
•
BPDate. Provide the BPate for the record to be validated/explained.
•
EncodeID. Provide the participant unique ID number for the record to be
validated/explained.
•
MDE Item Number. Provide the MDE item number associated with the error, quality
check, or other value for validation/explanation.
•
MDE Value. Provide the value or code (e.g., numeric value for height, ‘7 unknown’) to
be verified/explained.
•
Explanation. Provide an explanation for the value (e.g., review of hard-copy record,
discussion with provider verified value).
WISEWOMAN MDE Manual
Edition 18.3
B.6
Participant ID Change Form
The Participant ID Change Form should be filled out when a participant’s Encode ID has
changed since a previous submission. The correct Encode ID for a participant is needed to
track participant data over time. Each value in the form (which is available on the web-based
WISEWOMAN Data Management System 3.0) should be reviewed and verified by your
program staff. To complete this form, go to the Miscellaneous Forms tab on the Data
Management System 3.0 and select "Go to Participant ID change records." Select "Create
New Participant Change Record" for each ID that changed. The following information is
needed for each changed ID:
•
StFIPS. Provide your state or tribal code as entered for the participant with the new
Encode ID.
•
OrigEncodeID. Provide the original participant unique ID number for the participant.
•
NewEncodeID. Provide the new, changed participant unique ID number for the
participant.
•
ChangeDate. Provide the date that the EncodeIDs were changed.
•
ReassignedDate. If the original EncodeID has been reassigned to a new participant,
provide the date of the reassignment here; otherwise, leave this field blank.
WISEWOMAN MDE Manual
Edition 18.3
B.7
Correction to Previous MDE File Form
The Correction to Previous MDE File Form may be filled out when modifications have been
made to a screening record that had been previously submitted to CDC. Recipients are not
required to submit this form, but may choose to submit it if they would like to provide an
explanation to CDC about significant updates or corrections made to previously submitted
data.
Each value in the form (which is available on the web-based WISEWOMAN Data
Management System 3.0) should be reviewed and verified by program staff. To complete this
form, go to the Miscellaneous Forms tab on the Data Management System 3.0 and select
"Go to MDE Correction Form." Select "Create New MDE Correction Record" for each record
change to be documented. The following information is needed for each corrected record:
•
StFIPS. Provide your state or tribal code as entered for the participant with the new
Encode ID.
•
EncodeID. Provide the original participant unique ID number for the participant.
•
Office Visit. Provide the office visit date (BPDate) for the screening that the
corrections affect.
•
Screening Number. Provide the number of screenings received by the participant
(NScreen) as of the screening that the corrections affect.
•
Type of Revision. Select one of the following options from the dropdown menu:
Added New Records for previous periods, Edited Existing Record, Dropped Records
for previous period
WISEWOMAN MDE Manual
Edition 18.3
B.8
Supplemental Lifestyle Program and Health Coaching (LSP/HC) Session Spreadsheet
The current MDE file format allows for documentation of up to two LSP/HC referrals and up to
16 LSP/HC sessions for each screening. If a participant receives more than two LSP/HC
referrals and/or attends more than 16 LSP/HC sessions, recipients may choose to record and
submit these data to CDC for the purposes of program monitoring and/or evaluation.
Each value in the form should be reviewed and verified by program staff. The form and
detailed instructions for completing the form are available under the DMS Documents Library
of the WISEWOMAN Data Management System 3.0. The instructions include examples for
completing the form when a participant attends more than 16 LSP/HC sessions associated
with a screening and when a participant receives more than two LSP/HC program referrals
associated with a screening. The supplemental form should be uploaded under the
Miscellaneous Forms tab by selecting “Go to Upload Supplemental Forms” and then “Upload
New Supplemental Form.” The following fields are included the in the form:
•
Screening Number. Provide the number of screenings received by the participant
(NScreen) as of the screening associated with the HC/LSP.
•
EncodeID. Provide the original participant unique ID number for the participant.
•
BPDate. Provide the office visit date (BPDate) for the screening (baseline screening or
rescreening) that the corrections affect.
•
RefDate. Provide the date of the HC or LSP referral.
•
Intervention. Provide the HC or LSP session dates.
WISEWOMAN MDE Manual
Edition 18.3
B.9
APPENDIX C:
DATA ANALYSIS AND USE
MDEs provide a rich source of data for the WISEWOMAN Program. CDC and recipients use
MDEs in a variety of ways to monitor and assess progress and performance. This Appendix
describes the data summary report generated with every submission and other data uses for
the MDEs by CDC. It also discusses potential ways in which recipients can use the data.
Data Summary Report Format and Content
MDE data submissions are used to generate biannual program-specific and aggregate MDE
reports. CDC and recipients use these reports to gauge program progress in meeting goals
and identify areas for improvement. For example, CDC project officers may use these reports
to help identify areas for technical assistance, and recipients may use them to detect areas
where further provider training is needed. Uses of MDE data are discussed in greater detail in
the subsections below.
Additional information about the data summary report format and content will be provided
once available.
Data Use by CDC
WISEWOMAN MDEs support three major objectives: 1) public health practice through
continuous program improvement, 2) program performance, and 3) assessing program health
outcomes through evaluation.
Potential Data Use by Funded Programs
Recipients use MDEs in a variety of ways to drive program improvement and track program
progress. Below are some examples of MDE use among funded programs.
•
Analysis of provider performance. Recipients have used MDEs to track the number
of screenings and LSP/HC sessions conducted by provider sites. In addition, some
have created program-level performance measures that they calculate for individual
providers.
•
Identification of areas for provider trainings. Recipients have used MDEs to
identify areas where provider sites were in need of training or technical assistance.
•
Assessment of performance in comparison to national benchmarks. Recipients
have used MDEs to assess the characteristics and risks of the population served in
comparison to that for their entire state or the nation.
•
Assessment of participant changes in risk factors. Recipients have used MDEs to
analyze changes between participants’ baseline screening, rescreening, and follow-up
screening visits.
Recipients interested in receiving technical assistance related to using MDEs as a data
source for program monitoring and evaluation should contact their project officer.
WISEWOMAN MDE Manual
Edition 18.3
C.3
APPENDIX D:
TECHNICAL ASSISTANCE RESOURCES
To support recipients in collecting and submitting data, CDC has developed several
strategies and tools to provide technical assistance to recipients. This appendix describes the
various types of technical assistance available to recipients, the web-based WISEWOMAN
Data Management System 3.0, the method for requesting individualized technical assistance,
and the technical assistance Helpdesk.
Types of Technical Assistance Available
Technical assistance available to recipients can be broadly categorized as individualized
technical assistance, group technical assistance, and tools. Below, specific types of technical
assistance/tools within these categories are described. The table at the end of this subsection
summarizes the types of technical assistance/tools by category, provider, and timeline.
Individualized Technical Assistance
•
Data Review Calls. After each MDE submission, summary reports are generated and
may be reviewed with recipients during a data review call. As needed, data quality
reports and other materials may also be reviewed.
•
Helpdesk Requests. Recipients can request individualized technical assistance
through the Helpdesk ([email protected]). A health scientist
from the CDC data team will collaborate with the data contractor to respond to
technical assistance requests. This type of assistance is tailored to the recipient and
the question. More information is provided in the following subsections of this
appendix, “Requesting Individualized Technical Assistance” and “Helpdesk for
Technical Assistance Requests.”
Group Technical Assistance
•
Ad Hoc Data Calls and Trainings. Throughout the course of the year, data issues
affecting a majority of or all recipients may be identified, either through individualized
technical assistance or as a result of changes to the MDE submission process and
specifications (e.g., modification of MDE specifications, added MDE variables). As a
result, trainings or group communications may be needed. If the need for these
trainings or group communications cannot be fulfilled at the annual meeting, ad hoc
data calls and trainings will be held.
Tools
•
WISEWOMAN MDE Manual. This manual is a technical assistance tool for recipients.
It provides detailed guidance on the MDE submission process and MDE specifications,
and it will be updated as necessary to stay current with the data submission and
collection requirements. Recipients can access the current edition in the
WISEWOMAN Data Management System 3.0 (wwwn.cdc.gov/wisewoman).
•
Edits Documentation (SQL Spreadsheet). The edits documentation details all the
edits programmed in the validation tool. The documentation provides the coding used
for validation in plain language. It also documents the changes to the edits from the
previous MDE edition. Recipients can access the current edition in the WISEWOMAN
Data Management System 3.0 (wwwn.cdc.gov/wisewoman).
As needed, other tools may be disseminated to recipients.
WISEWOMAN MDE Manual
Edition 18.3
D.3
Summary of Types of Technical Assistance and Tools Available
TA Type
Provider
Timeline
Individual
Data review calls
Project officers and/or data
contractor
Semiannually, after MDE
submission and release of
data summary reports
Helpdesk requests
Data contractor
As needed
Data contractor
As needed
WISEWOMAN MDE Manual
Data contractor
Ongoing
Edits documentation
Data contractor
Ongoing
Group
Ad hoc data calls and
trainings
Tools
Helpdesk for Individualized Technical Assistance Requests
Technical assistance may be requested through by emailing the data contractor at
[email protected]. 1 Once a request for technical assistance related
to MDEs is received, Helpdesk will automatically confirm receipt of the request and
collaborate with the Health Scientist to resolve the request. For more complex requests or
those requiring project officer input, responses may take more than 24 hours.
All requests are tracked by Helpdesk staff and the health scientist; this is to ensure that
follow-up is completed for all requests and that responses are satisfactory to the requester. In
addition, project officers will be kept abreast of the technical assistance needs of their
programs. The tracking of technical assistance requests by the Helpdesk, health scientist and
project officers allows CDC to identify common issues to inform Program-wide technical
assistance.
1 Recipients may also choose to telephone individual members of the data contractor team. However, requesting technical
assistance through email or website guarantees that all data contractor team members receive notification of the request,
and therefore requests are more likely to receive a prompt response.
WISEWOMAN MDE Manual
Edition 18.3
D.4
APPENDIX E:
PERFORMANCE MEASURES
1. Increased reporting monitoring, and tracking of clinical data for improved identification,
management, and treatment of women with high blood pressure
Number and percentage of WISEWOMAN participants whose WISEWOMAN provider
has a protocol for identifying patients with undiagnosed hypertension.
2. Increased use of and adherence to evidence-based guidelines and policies related to
team-based care.
Number of percentage of WISEWOMAN participants whose WISEWOMAN provider
has policies or systems to implement a multi-disciplinary team approach to blood
pressure control
3. Increased use of data systems to identify and refer at risk women to appropriate
healthy behavior support services.
Number and percentage of at-risk women in WISEWOMAN referred to an appropriate
healthy behavior support service
4. Increase data sharing and utilization (e.g. through a bi-directional feedback
mechanism)
Number and percentage of WISEWOMAN providers with an implemented community
referral system (tracking bi-directional referrals) for healthy behavior support services
for people with high risk for CVD.
5. Increased participation in healthy behavior support services resulting in improved and
maintained healthy behaviors and lifestyle changes.
Number and percentage of women in WISEWOMAN referred to a healthy behavior
support service who attend at least one session.
6. Improved blood pressure control
Number and percentage of women in WISEWOMAN with known high blood pressure
who have achieved or are currently maintaining blood pressure control.
WISEWOMAN MDE Manual
Edition 18.3
E.3
APPENDIX F:
NUTRITIONAL PROMPTS
WISEWOMAN MDE Manual
Edition 18.3
F.3
Source:American Heart Association’s
Life’s Simple 7
WISEWOMAN MDE Manual
Edition 18.3
F.4
Source:American Heart Association’s
Life’s Simple 7
WISEWOMAN MDE Manual
Edition 18.3
F.5
Source:American Heart Association’s
Life’s Simple 7
WISEWOMAN MDE Manual
Edition 18.3
F.6
Source:American Heart Association’s
Life’s Simple 7
| File Type | application/pdf |
| File Title | WISEWOMAN Program MDE Manual |
| Subject | heart disease, data elements, center for disease control, WISEWOMAN, integrated health |
| Author | Centers for Disease Control & Prevention;WISEWOMAN |
| File Modified | 2023-04-03 |
| File Created | 2019-09-04 |